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Abstract 
The implication of the innate immune system on inflammatory carcinogenesis is a central topic 
in tumor biology. The humoral pattern recognition molecule PTX3 plays a fundamental role in 
the modulation of inflammation by regulating Complement cascade and P-selectin dependent 
neutrophil recruitment. Available information in human and murine 3-MCA induced sarcomas 
suggests a protective role of PTX3 in cancer-related inflammation. In this study we showed that 
PTX3-deficient mice were more susceptible to DMBA/TPA chemically-induced epithelial skin 
cancer than PTX3-competent mice, in term of incidence, multiplicity of papillomas and number 
of lesions evolving to skin carcinomas, suggesting a more aggressive behavior of PTX3
-/- 
tumors. 
In the skin, PTX3 was strongly produced during the acute phase of carcinogenesis by infiltrating 
macrophages, neutrophils, and vessels. Immunohistochemical investigation of papillomas 
showed low presence of PTX3 in the extracellular matrix. The deficiency of PTX3 was 
associated with increased cancer-related inflammation in term of neutrophil infiltration, higher 
production of pro-inflammatory cytokines and chemokines, increased C3 and IgG deposition. In 
the effort to define the molecular mechanisms underlying this phenotype, we observed that P-
selectin deficiency and in vivo neutrophil depletion reverted the tumor susceptibility of Ptx3
-/-
 
mice. All together, these results provide evidence that PTX3 is locally produced and plays a 
protective role in epithelial skin carcinogenesis acting as an extrinsic oncosuppressor. The 
mechanism of PTX3-mediated protection is explained by modulation of cancer-related 
inflammation regulating P-selectin dependent neutrophil recruitment and Complement 
activation. 
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Introduction 
1 The link between inflammation and cancer  
 
1.1 Pathways that connect inflammation and cancer 
In 1863, Rodolf Virchow observed the presence of leukocytes in tumor microenvironment 
providing the first evidence regarding the links between inflammation and cancer
1
. However, 
only in the last decade research activity has supported this interaction giving the basis for a new 
strategy of cancer prevention and treatment. Mantovani et al. summarized the multiple 
connections between inflammation and cancer describing two pathways: an extrinsic and an 
intrinsic pathway
2
 (Fig. 1).  
 	
 
 
 
Fig. 1. Pathways that connect inflammation and 
cancer.  
Cancer and inflammation are related by intrinsic 
and extrinsic pathways.  
In the extrinsic pathway, chronic inflammation 
augments the risk to develop cancer. By contrast, 
the intrinsic pathway is activated by genetic events 
in oncogenes or tumor-suppressor genes that cause 
neoplasia. Transformed cells produce 
inflammatory mediators, thereby generating an 
inflammatory microenvironment also in tumors 
without a pre-existing inflammatory condition.   
The two pathways converge, resulting in the 
activation of transcription factors, mainly NF-κB, 
STAT3 and HIF1α in inflammatory cells, and 
tumour cells, resulting in a cancer-related 
inflammatory microenvironment.  
From: Cancer-related inflammation. Mantovani et 
al.; Nature. 2008. 
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The extrinsic pathway underlines the association of chronic inflammation with cancer risk. The 
majority of tumors are not hereditary but derive from environmental causes (chronic infection, 
obesity, tobacco smoke, silica or asbestos) that favor chronic inflammation. Prolonged infections 
for example with Helicobacter pylori, Hepatitis B or C viruses, Papillomavirus, increase the risk 
to develop gastric, hepatocellular and cervical cancer, respectively
3
. Moreover, autoimmune 
diseases promote tumor development, for instance, inflammatory bowel disease (IBD) is 
responsible for higher susceptibility to colorectal cancer
4
. Since inflammatory cell genome is not 
subject to gene mutations, differently from cancer cells, targeting the inflammatory 
microenvironment should be an unconventional strategy. Anti-inflammatory drugs, such as 
aspirin or cyclooxygenase 2 (COX-2) inhibitors, reduce the tumor incidence and progression of 
solid cancers such as colon, lung and prostate cancers
5
. However, other autoimmune disorders, 
for example psoriasis and rheumatoid arthritis, are not involved in tumorigenesis
2
. Chronic 
inflammation can contribute to carcinogenesis by increasing the proliferation of mutated cells, 
producing reactive oxygen species (ROS)
6
 that favor genetic instability and inducing 
oncosuppressor-gene methylation
7
 (Fig. 2).  
The intrinsic pathway explains how inflammatory cells and mediators are present within tumors 
in absence of well-documented chronic inflammation. This pathway is activated by oncogene or 
tumor-suppressor gene mutations. However, transformed cells produce inflammatory mediators 
favoring an inflammatory microenvironment within the tumor. For example, it has been 
described that alterations in RET gene, common in papillary thyroid carcinoma, promoted the 
production of inflammatory mediators including the pro-inflammatory cytokine interlukin1β (IL-
1β) and the activation of COX-2, which is involved in prostaglandin production8. Activation of 
RAS-RAF family
9,10
 or MYC
11
, frequently found in human and murine tumors, also promoted 
the production of tumor-promoting cytokines and chemokines.  
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The intrinsic and the extrinsic pathway converge in the activation of main transcription factors 
such as nuclear factor-κB (NF-κB), hypoxia-inducible factor 1α (HIF1α), signal transducer and 
activator of transcription 3 (STAT3), in tumor cells. These factors promote in turn the production 
of cytokines and chemokines, which recruit inflammatory cells and favor the establishment of an 
inflammatory microenvironment inside the tumor
2
. Chromosomal rearrangements of nf-kb 
family members have been found in many human carcinomas and lymphomas even if NF-κB 
activation in tumor cells is rarely a consequence of gene alterations
12
. NF-κB acts downstream 
the signaling of IL-1R family and MyD88 and plays an antiapoptotic role favoring the 
transcription of BCL-2 and BCL-XL. In addition, it promotes the transcription of angiogenic 
proteins such as angiopoietin and vascular endothelial growth factor (VEGF) and is involved in 
epithelial to mesenchymal transition (EMT), regulating the transcription of TWIST and KISS and 
matrix metalloproteases (MMP-2 and MMP-9). Moreover, NF-κB upregulates pro-inflammatory 
Fig. 2. (A) Role of Inflammation in tumor 
initiation. Inflammatory cells release ROS and 
reactive nitrogen intermediates (RNI), which 
increase the rate of mutations in neighboring 
stromal cells. In turn, cytokines produced by 
leukocytes favor ROS and RNI production by  
tumor cells. In addition, inflammation may 
promote epigenetic changes that favor tumor 
initiation.  
 
 
(B) Role of Inflammation in tumor promotion. 
Cytokines produced by infiltrating leukocytes 
activate key transcription factors, including NF-
kB or STAT3, in premalignant cells favoring 
tumor promotion. NF-kB and STAT3, in turn, 
stimulate the production of chemokines to sustain 
inflammation in the tumor microenvironment. 
From: Immunity, inflammation, and cancer. M. 
Karin; Cell. 2010. 
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cytokines (e.g. IL-1α, TNF-α, IL-23) and chemokine receptors (e.g. CXCR4), hypoxia inducible 
factor 1α (HIF1), and other genes that control pro-tumorigenic processes in both inflammatory 
and tumor cells
2,3,13
. The NF-κB pathway is closely controlled at different levels. In fact, NF-κB 
is normally sequestered by inhibitory proteins, IκBs, in the cytoplasm of unstimulated cells 
avoiding the translocation into the nucleus. Upon NF-κB–activating stimuli, IκB kinase (IKK) 
activation, depending on its phosphorylation, promotes IκB phosphorylation and degradation, 
allowing NF-κB to translocate into the nucleus. A variety of other signaling events, such as the 
phosphorylation of IKK, the promotion of IκB synthesis, the processing of NF-κB precursors and 
the phosphorylation of NF-κB provide additional mechanisms that regulate NF-κB activity. It 
has been described that TIR8, also known as single Ig IL-1 receptor (IL-R)-related molecule, 
SIGIRR, competed with MyD88 and IRAK recruitment at the TIR domain of TLR/IL-1R thus 
dampening the signaling pathway leading to NF-kB activation
14
. TIR8 played a protective role in 
murine models of colitis-associated cancer by modulating bacteria-induced TLR signaling and 
consequently production of inflammatory mediators
15
. However different roles of NF-κB have 
been described in different tumors such as its inhibiting role in murine models of skin 
carcinogenesis and hepatocellular carcinoma
6,16
.  
All this evidence suggests the presence of inflammatory cells, chemokines and cytokines in the 
tumor microenvironment in both animal models and humans from the earliest stages of tumor 
development. Furthermore, the targeting of leukocytes, inflammatory mediators, including 
chemokines and cytokines or transcription factors involved in inflammation (like NF-κB and 
STAT3) may represent a new therapeutic strategy in cancer.  
 
1.2 Balance between immune-surveillance and tumor-promoting inflammation 
At the end of the nineteenth century, the observation of tumor regression in cancer patients with 
postoperative infections led Coley et al. to administer a mixture of toxins into the tumors, 
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obtaining higher survival of individuals with advanced cancer
17
. Now it is well known that, as 
for pathogens, the immune system can recognize specific tumor-antigens and eliminate 
transformed cells through an extrinsic tumor-suppressor mechanism, known as 
immunosurveillance
18
. The interest in the field of tumor immunosurveillance grew in the last 
decade after the observation that interferon γ (IFN-γ) or recombination activating gene-2 (RAG-
2) deficient mice had increased incidence than wild-type (WT) mice to 3-methylcholantrene (3-
MCA)-induced sarcoma
19
. However, Rag2
-/-
 sarcomas implanted in WT mice were more 
rejected, compared to WT sarcomas, indicating an higher immunogenic potential of tumors 
growing in immune-compromised animals
19
. Many observations suggest that tumor cells 
influence the immune system to avoid immune recognition and favor tumor-promoting 
inflammation. These data have led to develop a new concept defined tumor immunoediting, 
which explains the dynamic process of tumor immune-surveillance including elimination, 
equilibrium and escape phases
18
 (Fig. 3). In this regard, the injection of tumor cells cannot be 
considered a good model that mimics the first phase of carcinogenesis because it has already 
escaped cancer immunity, differently from carcinogen-induced models of cancer. The most 
studied murine models of carcinogen-induced cancer are 3-MCA-induced fibrosarcoma and 
DMBA (7,12-di-methylbenz(a)anthracene) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) 
induced cutaneous squamous cell carcinoma (SCC). In the 3-MCA model, tumor-promoting 
inflammation and antitumor immunity overlap: in the first stage of carcinogenesis, inflammatory 
cells and molecules contribute to tumor induction until an antitumor immune system develops to 
eliminate transformed cells. Mice lacking for cells of adaptive immunity such as αβ or γδ T-
lymphocytes, and of innate immunity such as innate-like T cells, NKT cells, NK cells or 
eosinophils showed increased tumor susceptibility to 3-MCA-induced sarcoma
18
. Moreover, high 
number of soluble immune mediators (perforine
20
, TRAIL
21
) and cytokines (IL-12
22
, IFN-αβ23, 
IFN-γ20) were also involved in the first phase of tumor elimination. In particular, besides to favor 
the encapsulation of 3-MCA at the injection site, IFN-γ played an antitumor role enhancing 
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MHC class I expression on the tumor cell surface and favoring the recognition of tumor antigens 
by T-cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Cancer immunoediting. Cancer immunoediting is the emerging concept of immunosurveillance and 
consists of three dynamic phases: elimination, equilibrium, and escape. In the elimination phase, innate and adaptive 
immunity work together to destroy developing tumors. If cancer cell variants are not destroyed, they may enter the 
equilibrium phase, in which its outgrowth is prevented by adaptive immunity also for the lifetime of the host. 
Editing of tumor immunogenicity occurs in the equilibrium phase. However, tumors cells may develop defects in 
antigen processing or presentation and become insensitive to adaptive immunity. These cells can enter the escape 
phase and induce an immunosuppressive state within the tumor microenvironment. In this condition, tumor cells 
cause clinically apparent disease.  
From: Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. R. Schreiber et 
al.; Science. 2011. 
 
 
Furthermore, the two step model of DMBA/TPA, in which the pro-tumorigenic role of the 
inflammatory component is substantial, also highlights the coexistence of antitumor immunity
24
. 
For example γδ T-lymphocytes25 and CD8+ T cells conferred protection differently from CD4+ T 
cells
26
 and Langherans cells
27,28
. In addition, effector molecules and cytokines differently 
influenced DMBA/TPA-induced papilloma development, as we will discuss later. IL-12 
contributed to antitumor effect
22
, while IL-23
29
 and IL-17 promoted tumor growth
30,31
. 
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Surprisingly, IFN-γ played an opposite role in DMBA/TPA model compared to 3-MCA model23. 
This observation explains that the role of a single immune cell or molecule also depends on the 
tumor microenvironment.  
The equilibrium phase is the “immune-mediated tumor dormancy”18 in which antitumor 
immunity contains but does not eliminate residual malignancy. It has been showed that WT mice 
treated with low doses of 3-MCA displayed small stable masses at the site of MCA injection. 
The same treatments given with a mixture of monoclonal antibodies that deplete CD4
+
 and CD8
+
 
cells increased the fibrosarcoma growth compared to NK cell depletion. These data underline the 
importance of adaptive immunity in tumor dormancy
32
. 
The escape phase shows the defeats of the antitumor immunity to control tumor growth and 
derives from changes at the level of both tumor and immune cells. Results demonstrated that 
neoplastic cells could escape the immunosurveillance through central and peripheral tolerance in 
which T lymphocytes self-reactive against tumor antigens were eliminated in the thymus or 
periphery, respectively. Tumor cells also acquired defects in the machinery involved in tumor-
antigen processing and presentation. Changes in classical and non classical MHC class I 
antigens, as well as in the dimeric transporter associated with antigen processing, TAP1 and 
TAP2, and in β2-microglobulin (associated with the α chain of MHC class I molecules), have 
been identified in malignant cells. Furthermore, transformed cells lost the ligand for NKG2D 
limiting NK cell activation and expressed inhibitory ligands of T-cell cytotoxic activity such as 
B7-1, B7-2, HLA-G and PD-L1
18
. In addition, tumor cells avoided cancer immune-surveillance 
releasing immunosuppressive cytokines (IL-10, TGF-β, IL-4, IL-13) that attracted tumor-
associated macrophages (TAM), discussed below, and CD4
+
 CD25
+
 Foxp3
+
 regulatory T cells 
(Tregs) that inhibited cytotoxic activity of CD8
+
 T cells.  In particular, it has been showed that 
TGF-β inhibited dendritic cell (DC) activation, captured aminoacids necessary for T cell function 
and converted effector T cells in Tregs. Different immune mediators such as cytokines and 
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chemokines drive the direction of the balance between antitumor (IL-12, IFN-γ) and tumor-
promoting inflammation (IL-6, TNF-α, IL-17, IL-23)18 (Fig. 4).  
 
 
 
 
Fig. 4. Balance between Immunosurveillance and Tumor-promoting inflammation. Tumor-promoting 
cytokines including IL-6, IL-1, IL-23 and IL-17 act on immune and malignant cells to move the balance toward 
tumor promotion. As a consequence, knowledge of soluble mediator profile for each tumor can be more relevant 
than tumor-infiltrating lymphocytes. 
From: Immunity, inflammation, and cancer. M. Karin; Cell. 2010. 
 
As a consequence, knowledge of soluble mediator profile for each tumor can be more relevant 
than tumor-infiltrating lymphocytes.  
This paragraph emphasizes the concept that the immune system does not only defend the host 
against tumor development but also has the ability to promote tumor growth. These dual effects 
of the immune system on developing tumors lead to redefine the cancer immunosurveillance 
hypothesis into the dynamic concept of cancer immunoediting. 
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1.3 Tumor-associated macrophages (TAMs) and the emergent role of tumor-associated 
neutrophils (TANs) and myeloid derived suppressor cells (MDSCs) in tumor progression 
Macrophages are the most abundant leukocytes in the tumor microenvironment involved in all 
phases of tumor progression including tissue remodelling, tumor cell growth, angiogenesis, 
invasion, extravasation and metastasis
33
. Several lines of evidence highlighted the correlation 
between TAM and poor prognosis such as in Hodgkin’s lymphoma, gastric cancer, head and 
neck squamous carcinoma
34
. Surprisingly, in colorectal cancer (CRC) their role seemed to 
depend on localization: peritumoral macrophages showed better prognosis compared to 
intratumoral infiltrate
35
.  
The bone marrow (BM) is the primary source of monocytes that originate TAMs
36
. Circulating 
BM-derived LY6C
+ 
murine
 
monocytes were recruited at the tumor site by the chemotactic factor 
CCL2/MCP-1 (originally described by Bottazzi et al. in 1983). High levels of CCL2 in tumors 
were associated with bad prognosis and CCL2 depletion reduced TAM number and lung 
metastasis in a mammary carcinoma
37
. Recently, the splenic red pulp of tumor-bearing mice has 
been identified as a reservoir of TAMs driven to the tumor through CCR2 signalling
38
. New 
evidence demonstrated the CSF-1 and STAT-1-dependent proliferative capacity of TAMs in a 
genetically engineered murine model of breast cancer
39
. Subsequent investigations are necessary 
to confirm the accumulation of self-maintained TAMs in human cancer. 
Macrophages are versatile leukocytes characterized by strong plasticity over-simplified, as 
discussed by Mantovani, through an M1/M2 nomenclature
40
. M1 macrophages are classically 
activated by Th1 cytokines such as IFN-γ, TNF-α or microbial stimuli like lipopolysaccharides 
(LPS). They express inflammatory cytokines such as IL-1β, IL-12, TNF-α, IL-6, IL-23 and 
chemokines like CXCL9, CXCL10 and produce reactive nitrogen species (RNS) through iNOS. 
M1 cells play anti-microbial and anti-tumor function and drive Th1 response. In particular, IL-12 
favors NK cell and cytotoxic T lymphocyte (CTL) activation
34,35
.  
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In contrast, M2 macrophages are activated by Th2 anti-inflammatory cytokines such as IL-10, 
IL-4, IL-13, TGF-β and chemokines including CSF-1/M-CSF, CCL5, CCL7 and CCL8. They 
release immunosuppressive cytokines, such as IL-10, TGF- β, that promote Th2 response. In 
addition, these cells release anti-inflammatory chemokines like CCL17, CCL18, CCL20, CCL22 
and CCL24, which attract Tregs and avoid CTL response. M2 macrophages are poor antigen 
presenting cells (APC) and display pro-tumor functions. The expression of Ym1, Fizz1, Arginase 
1 and scavenging receptors is typical of M2 murine macrophages
34,35
 (Fig. 5).  
 
 
Fig. 5. Spectrum of macrophage polarization. The figure represents a simplified scheme showing macrophage 
phenotype, with M1 and M2 states representing two extremes of this continuum. Variation among the M2 state is 
indicated as M2-like phenotype. The most key polarizing stimuli, phenotypic features, and functions are presented 
for M1 and M2 macrophages. The expression of Ym1, Fizz1, and Mgl2, as well as the NOS versus Arg phenotypes, 
is specific to M2 polarized mouse macrophages. Similarly, the expression of CCL17, CCL18, CCL22, and CCL24 
are found in human M2-polarized macrophages.  
From: Tumor-associated macrophages: functional diversity, clinical significance, and open questions. S. Biswas et 
al.; Semin Immunophatol. 2013. 
 
Several data support the M2-like phenotype of TAMs in both human and murine tumors 
although this cannot be generalized to TAMs in different tumor regions. Van Ginderachter et al. 
identified at least two TAM subsets on the basis of Ly6C, MHC class II, CX3CR1 and CCR2 
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expression in mouse lung carcinoma: CD11bhiF4/80hiLy6Clo TAM subsets, defined as MHC-IIlo 
and MHC-II
hi 
TAMs. Both subsets derived from the same Ly6C
hi
 tumor-infiltrating monocyte 
precursor (LY6C
hi
CCR2
hi
CX3CR1
int
MHC class II
-
), but were located in different oxygenized 
regions. MHC-II
lo
 TAMs resided in more hypoxic regions and expressed higher levels of M2 
markers like arginase and hypoxia-regulated genes than MHC-II
hi
 TAMs. Hypoxia did not alter 
the number or the polarization of tumor-infiltrating macrophages, but regulated the expression of 
some M2-like genes such as iNOS, GLUT-1, VEGF and hypoxia responsive genes in MHC-II
lo
 
TAMs
41,42
. As a result, the definition of macrophage subsets in different tumors is necessary to 
define the strategy of treatment. 
As mentioned, TAMs influence many aspects of tumor progression such as tumor angiogenesis. 
When tumors exceed in diameter they need new blood vessels carrying nutrients and oxygen. 
Hypoxia led HIF-1 α activation which in turn promoted the transcription of genes favoring tumor 
angiogenesis (such as VEGF, EGF, IL-8, IL-6, TNF-α, TGF-β) in both tumor cells and in 
resident macrophages
43
. In particular, Tie2
+ 
macrophages (TEMs) had potent angiogenic 
property and the Tie2 ligand, angiopoietin-2 (Ang-2), favored TEM distribution along blood 
vessel surface. M-CSF displayed pro-angiogenic functions up-regulating Tie2 on TEM surface
44
. 
In addition, TEMs favored tumor cell intravasation forming clusters with neoplastic cells around 
blood vessels. Depletion of Tie2
+
 TAMs affected angiogenesis and metastasis
45
. In addition, 
TAMs are rich source of matrix-degrading proteases such as MMP-2, MMP-7, MMP-9, MMP-
12, plasmin, urokinase-type plasminogen activator (uPA), which are know to promote pro-
angiogenic factor release in the extracellular matrix 
43
.  
Among the protumoral mechanisms, TAMs, as well as tumor cells, expressed non classical MHC 
class I molecules such as HLA-G, which limited NK cell activation through the binding to 
NKG2D
33
. In addition, TAMs produced ligands such as PD-L1, PD-L2, B7-1 and B7-2 for 
inhibitory receptors including PD-1 and CTLA-4 expressed on T-cell surface, favoring thereby 
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anergy of self-reactive T-cells. More simply, MHC
low 
TAMs displayed weak antigen presenting 
capacity to T-cells
33
. 
As described, TAMs directly secreted an array of immunosuppressive cytokines such as TGF-β, 
and IL-10, which dampened CTL functions and up-regulated Foxp3 in CD4
+
 T cells, 
respectively. Moreover, chemokines recruited Tregs showing another indirect 
immunosuppressive mechanism
33
.  
As discussed above, M2-like TAMs expressed high level of Arginase 1 which exhausted 
arginine residues necessary for the membrane expression of CD3 ζ chain, preventing T-cell 
function
46
. Furthermore, it has been described that TAMs promoted metastasis through the 
formation of pre-metastatic niches which enhanced homing of circulating tumor cells
47
. In fact, 
TAM depletion showed reduced lung metastasis in murine breast cancer
48
.  
This evidence suggests a new therapeutic strategy to target specific TAM subsets in each human 
tumor (by depletion or repolarization) or their pro-tumorigenic mechanisms, described above
33
. 
Interesting perspectives derived from the use of the chemotherapeutic agent, Trabectedin, which 
selectively depleted mononuclear phagocytes, including TAMs, through the activation of 
caspase-8
49
.  
 
Despite copious studies regarding the role of TAMs in the tumor microenvironement, many 
results have increased the interest on tumor-associated neutrophils (TANs). A recent published 
meta-analysis concerning 20 articles and 3946 patients have evaluated the prognostic value of 
TANs in different human cancers. The results of this analysis indicated the association between 
high density of intratumoral neutrophils and unfavorable survival in head and neck carcinoma, 
non-small-cell lung cancer and renal carcinoma, but not in gastric cancer. The authors have 
discriminated among intratumoral, peritumoral and stromal infiltrate, but the low number of 
papers regarding the last two compartments prevented statistics. In addition, this work showed a 
better prognostic value of CD66b as human TAN marker than CD15
50
.  
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Fridlender et al. have recently demonstrated that like TAMs, also TANs could feel the influence 
of the tumor microenvironment and polarize versus N1/N2 neutrophils in a murine model of 
transgenic lung adenocarcinoma and mesothelioma cell line transplantation. As reported, N1 
neutrophils displayed an anti-tumor phenotype with high levels of neutrophil attractant CXCL 
chemokines and low level of Arginase1. In addition, they promoted CD8
+ 
T cell recruitment 
releasing chemokines like CCL3, CXCL9 and CXCL10. In vitro experiments showed higher 
capacity of N1 neutrophils to kill neoplastic cells compared to N2 cells.  
TGF-β was the main actor for N2 polarization: TGF-β blocking, through the inhibitor SM16, 
increased N1 neutrophils, and their depletion promoted tumor growth
51
.  
Furthermore, IFN-β knockout (KO) mice, transplanted with fibrosarcoma or melanoma cells, 
showed faster tumor growth with more blood vessels than WT mice. Granulocyte depletion 
reverted the phenotype of IFN-β KO tumors. In fact, IFN-β favored N1 polarization 
downregulating transcription factors such as STAT-3 and c-myc that regulated pro-angiogenic 
factors like VEGF, CXCR4, CXCL12 and MMP9 in neutrophils
52
.  
Recently, Fridlender et al. have studied how tumor microenvironment could influence TAN 
phenotype during tumor progression in two murine models of tumor cell transplantation. 
Although they did not find differences in term of neutrophil numbers, their localization switched 
from periphery to the core of the tumor, between early (7 days post injection) and late (14 days 
post injection) tumor progression. Moreover, TANs isolated from early tumors displayed higher 
capacity to kill co-cultured tumor cells than neutrophils from late tumors. Among the 
mechanisms by which early TANs displayed anti-tumor activity there was the higher production 
of TNF-α, H2O2 (described below) and NO compared to TANs from late tumors. Only depletion 
of TANs from late stages reduced tumor growth
53
. Thus, like macrophages, TANs display 
plasticity and play different roles during carcinogenesis depending on the microenvironment.  
Sansom et al have found a correlation between neutrophil chemokine receptor CXCR2 and 
tumor progression. CXCR2
+
 cells were almost all Ly6G
+
 cells, and CXCR2 was the main 
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regulator of their recruitment
54,55
. In particular they documented the resistance of Cxcr2 KO 
mice to DMBA/TPA-induced skin cancer. Myeloperoxidase (MPO)
+
 cells were almost absent in 
Cxcr2-deficient papillomas. Short-term depletion (2,5 weeks) of Ly6G
+
 cells in established WT 
papillomas reduced their number and size
56
.  
The mechanisms by which neutrophils influence tumor progression can be ROS dependent or 
not
35
. Upon pathogenic insults, neutrophils expressed oxidant-producing enzymes like NADPH, 
MPO and superoxide dismutase that caused high concentrations of ROS such as O2
--
, H2O2 and 
HOCl to resolve the infection. Interestingly, in 1975, Clark and Klebanoff showed the in vitro 
capacity of neutrophils to kill neoplastic cells through ROS activity, membrane-perforating 
agents and cytokines including TNF-α and IL-1β57.  
However, data from literature attested that high concentrations of ROS can be genotoxic for 
cells, favoring alterations such as single strand DNA damage and the formation of 8-oxo-7,8-
dihydro-20-deoxyguanosine (8-oxodG). In particular, MPO used H2O2 to generate the 
hypochlorous acid that promoted the formation of an adduct to the DNA, malondialdehyde-
deoxyguanosine (M1dG)
58
. It has been estimated that reactive oxygen species are responsible for 
tumor initiation in one-third of cancers
59
. 
Proteins released from neutrophil granules can also play a role in tumor initiation. For example, 
neutrophil elastase, through insulin receptor substrate-1 degradation, dissociated PI3K and 
activated the PDGFR proliferation pathway
60
. In addition human neutrophils secreted high levels 
of oncostatin M, a member of IL-6 family, when cocultured with breast cancer cells. TAN-
derived oncostatin M promoted VEGF production from neoplastic cells and increased invasion 
capacity of breast cancer cells
61
. Another in vitro study revealed that hepatocyte growth factor 
(HGF) released from neutrophils promoted invasiveness of cholangiocellular and hepatocellular 
tumor cells
62
.  
Both TAMs and TANs are involved in tumor progression releasing pro-angiogenic factors
63
. 
Neutrophils are the primary source of the potent pro-angiogenic factor VEGF during 
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physiological conditions such as the menstrual cycle
64
. However, it has been showed that 
neoplastic cells stimulated TAN recruitment by releasing potent neutrophil CXCL chemokines 
like CXCL8, CXCL1 (KC), CXCL5 and CXCL6 leading to tumor angiogenesis
57
. Mentzel et al. 
have shown a positive correlation between the number of neutrophils and microvessel density in 
high-grade human myxofibrosarcomas
57
. Matrix remodelling by activated TANs was a possible 
mechanism which released angiogenic factors such as MMP-9/gelatinase B. Coussens et al. have 
demonstrated that MMP-9-deficient mice displayed reduced keratinocyte hyperproliferation and 
incidence of skin tumors
65
. Differently from other cells, neutrophils did not release MMP-9 
assembled with its inhibitor (TIMP-1), making it quickly available
57
. Activated neutrophils also 
produced pro-angiogenic chemokines like CXCL8 that contributed to MMP-9 degranulation 
which in turn favored IL-8 activation
66
. In addition, Ferrara et al. have identified another potent 
pro-angiogenic factor released by neutrophils: Bv8. CSF-3 was the major positive regulator of 
Bv8 expression. Treatments with anti-Bv8 antibodies reduced CD11b
+
Gr
+
 cells, angiogenesis 
and tumor growth
67
. 
In addition to release pro-angiogenic factors, neutrophils also favored endothelial cell 
proliferation through cell to cell contacts involving specific integrins and selectins
63
.  
Finally, both TANs and endothelium released H2O2 which can activate the transcription factor, 
ETS-1, that regulated the expression of several angiogenic genes like u-PA, MMP-968. 
Many data also displayed the metastatic potential of neutrophils for example favoring the release 
of β2 integrin69. In another study, Tazawa et al. have demonstrated that when a poor tumorigenic 
and metastatic fibrosarcoma cell line (QR-32) was implanted in syngenic mice using a scaffold, 
which favored neutrophil recruitment, it became highly metastatic. In addition, granulocyte 
depletion in the early phase significantly supressed these re-acquired metastatic ability of tumor 
cells
70
. 
Finally, a recent discovery has linked circulating neutrophil extracellular traps (NET) to clot 
formation in several murine models of cancer like leukemia, lung and breast cancer. NET 
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formation caused cancer-associated thrombosis and could be a possible target in the effort to 
reduce the frequency of thrombosis and death in cancer patients
71
 (Fig. 6).  
 
 
Fig. 6. Emergent role of TANs in tumor growth and progression. TANs may exert both anti-tumoral and pro-
tumoral functions. TANs can mediate cancer cell killing through the release of ROS and neutrophil elastase. In 
contrast, ROS production can favor genetic instability. TANs promote tumor cell proliferation through elastase 
activity, sustain angiogenesis through VEGF, MMP-9 or Bv8 release, enhance neoplastic cell invasiveness 
producing soluble mediators (e.g. OSM and HGF) and suppress effective anti-tumoral CD8+ T-cell immunity 
through the expression of arginase driven by TGF-β�.  
From: Tumor associated macrophages and neutrophils in cancer. M. R. Galdiero et al.; Immunobiology. 2013. 
 
In addition to conditioning macrophages and neutrophils to express an immunosuppressive 
phenotype, the tumor microenvironment actively recruits and expands an heterogeneous 
population of immature myeloid cells which are strongly immunosuppressive
72
. Given their 
characteristics, Gabrilovich et al. suggested to call them “myeloid-derived suppressor cells 
(MDSC)”73. These cells were mobilized from BM by several tumor factors such as CSF-274, 
VEGF
75
, IL-1β76, S100A8 and S100A977, which favored their immunosuppressive phenotype. 
HMGB1 also promoted the recruitment of MDSCs from BM precursor cells and increased 
MDSC-mediated production of IL-10 favoring an M2 phenotype of TAMs
78
.  
MDSC composition changes among different tumor histotypes and localizations and depends on 
tumor-released factors in both mouse and human
79
. Accordingly, as for TAMs and TANs, it is 
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important not only to attest the presence of these cells, but above all, to characterize MDSC 
subsets. Initially, observations in tumor-bearing mice identified two markers responsible for 
MDSC phenotype: CD11b and Gr1
80
. Further characterization discriminated two main subsets: 
Ly6C
+
 monocytic MDSCs (MO-MDSCs) and Ly6G
+ 
granulocitic or polymorphonuclear MDSCs 
(PMN-MDSCs)
81
.  
      Different MDSC subpopulations displayed different mechanisms of immunosuppression. As 
described for TAMs, the metabolism of specific amino acids like L-arginine by ARG1 or iNOS 
reduced CD3 ζ chain expression and, as a consequence, T-lymphocyte proliferation46. Moreover, 
IFN-γ-regulated genes such as COX-2, iNOS and gp91phox also played a role in T cell 
suppression. In particular, COX-2 favored ARG1 induction whereas NADPH oxidase (Nox) 
subunit (gp91phox) converted oxygen in superoxide anions which induce CD8
+
 T-cell 
tolerance
82
.  
Another mechanism attributed to MDSCs consisted in simultaneous activity of both enzymes, 
Arg1 and iNOS, which produced ROS and peroxynitrite causing nitration of tyrosines within 
TCR/CD8 complex, that could not respond to specific tumor-peptide in MHC complex
82
.  
In addition to these immunosuppressive strategies, it has been described that ADAM17 at the 
plasma membrane of MDSCs reduced L-selectin expression on the surface of naive T 
lymphocytes, limiting their recruitment to the lymph nodes
72
.  
MDSCs expressed Galectin 9, which bound Tim-3 domain on T cells, thereby promoting their 
apoptosis
83
. Finally, MDSCs decreased the number and inhibited the function of mouse and 
human NK cells, especially through the interaction with the NK cell receptor NKp30 and 
through the release of TGF-β172. PMN-MDSCs interfered with T-cell-mediated activity mainly 
producing ROS, while F4/80
+
MO-MDSCs acted primarily through iNOS and Arg1, although the 
distinction was not so clear
79
. Blocking IFN-γ/Stat-1 impaired partially MO-MDSC 
immunosuppressive function
84
.  
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In humans it is more difficult than in mice to identify the population of MDSCs since the lack of 
a specific marker such as Gr-1. Recently, at least six human MDSC subsets have been described 
using a multicolor strategy
85
.  
Experiments conducted by Corzo et al. have provided the plasticity of MDSCs from the spleen 
of tumor-bearing mice, to assume a TAM-like phenotype in a condition of HIF-1α-driven 
hypoxia
86
. 
However, the relationship between N2 TANs and PMN-MDSCs remains unclear. Recently, 
Friedlender et al. have developed a trascriptomics analysis to compare mRNA profiles of these 
cells. This approach showed TAN as a distinct population enriched in chemotactic factors for T-
cells but also B-cells, macrophages and neutrophils
87
.  
Mounting evidence indicates that the tumour microenvironment may influence myeloid cells and 
convert them to display an immunosuppressive phenotype. Some immunosuppressive 
mechanisms are common to all myeloid cells, but others are unique to specific populations. 
Thus, targeting common mechanisms could be a possible therapeutic strategy for certain cancers. 
 
1.4 The role of Complement in tumor development  
Complement represents a first line of defence against pathogens or non self-cells (Fig. 7). During 
carcinogenesis genetic and epigenetic changes can also alter cell membranes and the 
glycosylation state, becoming an hallmark of cancer
88
. However, there is not experimental 
evidence supporting the recognition of tumor-associated antigens and further killing of nascent 
neoplastic cells by the complement system
89
. Indirect assumptions concerning the role of 
complement in immunosurveillance derived from the presence of several complement proteins in 
cancer patients. For example increased levels of the anaphylatoxin C3a and C5b-9 (membrane 
attack complex, MAC)
90
 and higher activation of the lectin pathway
91
 have been found in 
patients with ovarian cancer and colorectal cancer, respectively, than control patients. Moreover, 
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circulating levels of MASP-2 (MBL-associated serine protease-2) from the lectin-pathway have 
been associated with poor survival in CRC patients
91
.  
 
However, neoplastic cells displayed several strategies to influence immunosurveillance such as 
through the expression of negative complement regulators
88,89,92 
(Fig. 8). For example the 
overexpression of CD55 (C3 and C5 convertase decay-accelerating factors) has been found in 
prostatic tumors
93
. High levels in urine of the soluble factor H (FH), inhibitor of the alternative 
pathway, had a negative prognostic potential in bladder cancer
94
.  
The growing evidence regarding the expression of membrane-bound complement regulator 
proteins (mCRPs) by neoplastic cells has promoted the use of monoclonal antibodies (mAbs) 
that recognized tumor antigens to induce complement-dependent cytotoxicity (CDC). In fact, 
some of these mAbs, such as rituximab, an anti-CD20, have already been used to treat B-cell 
lymphoma
95
. 
Fig. 7. Cascade of events during the 
activation of the complement 
system. Simplified scheme of the 
pathways of complement activation. 
Pattern-recognition molecules such as 
C1q, MBL (mannose-binding lectin), 
or ficolins bind to surface structures 
and initiate the formation of the 
classical C3 convertase. The 
alternative C3 convertase results from 
spontaneous hydrolysis of C3 (tick-
over). The three complement 
pathways differ in their mechanisms 
of target recognition but converge in 
the activation of the central 
component C3, which is cleaved by 
C3 convertase into C3b and C3a. 
After this activation, C5 is cleaved, 
and the assembly of the pore-like 
membrane attack complex (MAC) is 
initiated. The enzymatic cleavage of 
C3 and C5 leads to the production of 
anaphylotoxins C3a and C5a, two 
important inflammatory mediators 
and chemoattractants.  
From R. Pio et al.; The Role of 
Complement in Tumor Growth in 
Tumor Microenvironment and 
Cellular Stress. Springer New York. 
2014. 
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Fig. 8. Main complement inhibitors: soluble proteins and membrane-bound complement regulatory proteins. 
Red lines represent inhibitory activity (when ending in a bar) or accelerated decay activity (when ending in a 
square). Green lines represent cofactor activity (when ending in a square) or protease activity (when ending in an 
arrowhead).  
From R. Pio et al.; The Role of Complement in Tumor Growth in Tumor Microenvironment and Cellular Stress. 
Springer New York. 2014. 
 
Among other mechanisms that cancer cells used to avoid complement activation, Moskovich et 
al. have documented the elimination of MAC through endocytosis process
96
. In addition, 
membrane sub-lytic levels of MAC activated proliferative and anti-apoptotic pathways
97
. 
 
Beyond the CDC mechanism to eliminate nascent tumors, emerging researches have also 
demonstrated a tumor-promoting role of complement, especially in murine models of cancer 
(Fig. 9). Since C3 convertase formation and the conversion of C3 in C3b are the point in 
common for the three pathways of complement activation, the elimination of C3 blocks 
complement effector functions and allows the study the role of complement in murine models of 
cancer. Markiewski et al. have shown that after subcutaneous injection with TC-1, a cervical 
tumor cell line, tumor growth was significantly reduced in the absence of C3
98
. In addition, these 
authors have investigated the role of the anaphylatoxin C5a, a potent chemotaxin and pro-
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inflammatory mediator, in the same tumor model. C5aR deficiency also impaired tumor growth 
and progression
98
. The same results have been obtained treating 3LL-transplanted tumors with an 
antagonist of the C5aR
99
. In addition, in a genetic model of ovarian cancer, C3 or C5aR-deficient 
mice displayed smaller and less vascularized tumors than controls
100
. 
 
 
 
Fig. 9. Potential tumor-promoting roles of complement proteins in the tumor microenvironment.  
From R. Pio et al.; The Role of Complement in Tumor Growth in Tumor Microenvironment and Cellular Stress. 
Springer New York. 2014. 
 
An important evidence showed that C5aR blocking significantly reduced MDSCs and 
immunosuppressive genes (ARG1, CTLA-4, IL10, PDL1) 99. C5a acted as chemoattranctant for 
MDSCs into tumors
98
. Gunn et al. have found a positive correlation between C5a levels and Treg 
differentiation in a lymphoma model, suggesting that complement may also regulate Tregs
101
. 
The interaction between iC3b (fragment of C3b) and complement receptor-3 (CR3) up-regulated 
the expression of immunosuppressive cytokines (IL-10 and TGF-β) favoring MDSC 
recruitment
102,103
. 
It has been described that, under hypoxia, lung cancer cell lines down-regulated mRNA 
expression of complement regulators like FH, factor I and CD55 favoring complement activation 
and C3b deposition which could promote cancer progression
104
.  
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Complement may affect tumor progression also playing a role in angiogenesis. There are 
controversial studies regarding this issue, therefore more investigations are necessary. C5a 
stimulated human endothelial cell chemotaxis and tube-like formations in vitro
99
. In ovarian 
cancer, C5a deficiency impaired tumor growth and angiogenesis, suggesting the pro-angiogenic 
role of complement in tumor progression
88
.  
Finally complement can also play a role in tumor progression. Tang et al. have demonstrated that 
C3a reduced the expression of E-cadherin promoting EMT and consequently invasion and 
metastasis
105
. Moreover, it has been shown that anaphylatoxins C3a and C5a recruited BM-
derived mesenchymal stem cells into the tumor, favoring the mesenchymal transition
106
. 
Complement proteins can also trigger the degradation of the extracellular matrix. Results showed 
that C5a promoted the release of MMP-9 by C5aR-expressing macrophages
107
.  
As discussed, the recognition of cancer cells by complement may be an element of 
immunosurveillance. However, new evidence suggests that when complement fails to protect the 
host from growing tumor, the balance can move toward tumor-promoting inflammation. 
 
1.5 Important evidence regarding squamous epithelial carcinogenesis: from the role of 
Mast Cells (MCs) to Circulating Immune Complexes and FcγR activation 
In 1999, Coussens et al. have demonstrated the angiogenic potential of mast cells (MCs) in a 
murine model of SCC in which the early region genes of human papillomavirus type 16 
(HPV16) were under control of skin keratin 14 promoter/enhancer. As showed, dysplastic 
lesions were characterized by angiogenic switch from distal to subepithelial location of dilated 
blood vessels. MC density increased strongly in the dermal tissue of dysplastic lesions (3-6 
months) compared to hyperplastic (1 month) and normal skin. Moreover, angiogenic dysplasia 
displayed higher activity of MC-specific tryptase/MCP-6 and chymase/MCP4. Tryptase favored 
fibroblast proliferation in vitro, while chymase acted as angiotensin II-forming enzyme which 
promoted angiogenesis through the activation of VEGF and MMP-9
108
. Chymase also converted 
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IL1β, TGF-β and MMP-9 precursors to their active form109. MC deficient mice (with the loss of 
c-Kit) displayed a reduction of skin vascularization and keratinocyte proliferation at 2 months of 
age. These data support the pro-tumorigenic role of MC during early epithelial carcinogenesis 
possibly through the regulation of angiogenesis in HPV16 mice
108
.  However, several data 
indicated that MC could switch from the production of immunosuppressive cytokines like IL-4, 
IL-10, TGF-β, to pro-inflammatory ones, such as IL-6, which converted T-regs into Th17 cells. 
In addition, the protective role of MCs, in a murine model of CRC, indicated the need to 
characterize their phenotype in each tumor (tryptase
+
, chymase
+
 or both)
109
. 
De Visser et al. have shown that early lesions of HPV16 mice were characterized by abundant 
C3 deposition in dermal compartment. However, HPV16/C3
-/-
 mice displayed the same number 
of MCs and neutrophils (the two most abundant cells infiltrating HPV16 lesions) compared to 
HPV16 mice at early phases of tumor progression. These data indicated that C3 was not involved 
in MC and neutrophil recruitment. Moreover, the authors verified the involvement of C3 in MC 
activation (in term of angiogenic factor release) but the absence of angiogenic variations between 
HPV16/C3
-/-
 and HPV16 early lesions excluded this contribute.  
Dysplastic skins from HPV16 mice displayed an abundant dermal IgG1 deposition that could 
activate FcγR on inflammatory cell surface, recruiting MCs and neutrophils. As consequence the 
authors have speculated a complement-independent but antibody-dependent regulation of 
epithelial squamous carcinogenesis
110
.  
Subsequent analysis investigated the role of adaptive immunity in the activation of innate 
immune response in early HPV16 lesions. HPV16/RAG
-/- 
mice, deficient for B and T-cells, 
showed reduced inflammation in terms of less MC and granulocyte infiltration. In addition, 
HPV16/RAG
-/- 
lesions displayed reduced levels of VEGF-A, CD31
+
 cells and epithelial 
proliferation versus HPV16 skin. B and T cell-deficiency drastically decreased carcinoma 
incidence.  Since CD4
+
 or CD8
+
 T cell deficiency did not affect leukocyte infiltration of early 
lesions, de Visser et al. have hypothesized the pro-tumorigenic role of B cells. However, B-
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lymphocytes did not infiltrate skin lesions but released Igs (IgM and IgG1 predominantly), 
which in turn could activate complement, bind leukocyte receptors and form immune-complexes. 
HPV16 serum transfer into HPV16/RAG
-/- 
mice restored premalignant characteristics like 
HPV16 B-cell transfer, indicating the protumorigenic role of B cell soluble factors in the early 
phases of epithelial squamous carcinogenesis
111
.  
Andreu et al. have showed that HPV16 deficient mice for B220
+
CD19
+
 B cells (HPV16/JH
-/-
) 
displayed a reduced infiltration of MC and Gr1
+
 cells, lower CD31
+
 vessels and keratinocyte 
proliferation, such as HPV16/RAG
-/- 
mice, suggesting the peculiar role of B cells in premalignant 
progression. Moreover, HPV16 IgG injection in WT mice was sufficient to induce inflammatory 
response, demonstrating the premalignant role of antibodies. In addition, the authors have found 
higher levels of circulating immuno-complexes, CICs, (IgG/C3; IgG/C1q) in HPV16 IgG 
compared to WT IgG. Since HPV16/FcγR-/- mice showed reduced MC and granulocyte 
infiltration and angiogenesis, it has been speculated the FcγR-dependent pro-tumorigenic role of 
CICs in HPV16 mice. CICs may activate FcγR on MC surface promoting angiogenesis and early 
tumor progression in HPV16 mice (Fig. 10). In addition, they have demonstrated that B cells and 
FcγR drove M2 polarization of TAMs during squamous carcinogenesis112.  
Because B cells regulate squamous carcinogenesis, and Tnf
−/− 
mice
113
, resistant to DMBA/TPA 
skin cancer, display B cell defects, Schioppa et al. have speculated that B cells were important 
effector cells for TNF-α–mediated promotion of cancer development. Splenic B-cells, isolated 
from DMBA/TPA-treated WT mice, injected in Tnf
−/− 
mice, significantly increased papilloma 
number. In contrast, TNF-α defective B cells failed to restore papilloma development in Tnf−/− 
mice, suggesting the protumorigenic role of TNF-producing B cells in DMBA/TPA-induced skin 
cancer
114
.  
These findings support a model in which activated B cells, CICs and FcγR-activated MCs and 
neutrophils promote chronic inflammation and favor epithelial squamous carcinogenesis. 
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Fig. 10. Activation of the FcγR pathway in SCC. In a genetic model of SCC in which the early region genes of 
human papillomavirus type 16 (HPV16) is under control of skin keratin 14 promoter/enhancer it has been 
demonstrated the protumorigenic role of soluble B-cell mediators such immunoglubulins (Igs). Igs accumulate in 
dermal stroma of neoplastic tissue as vasculature becomes angiogenic, and interact with FcγRs on resident and 
recruited myeloid cells. This interaction stimulate mast cell and neutrophil bioeffector functions such as tissue 
remodelling, survival/proliferation, angiogenesis, favoring malignant conversion.  
From: FcRgamma activation regulates inflammation-associated squamous carcinogenesis. L. Coussens et al. Cancer 
Cell. 2010. 
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1.6 Fundamentals of multi-stage DMBA/TPA-induced chemical carcinogenesis and the 
specific contribution of IL1R-MyD88-NF-κB and IL-23/IL17-pStat3 signalling pathways in 
skin cancer 
The skin represents the first line of defence against pathogens as physical barrier and reservoir of 
TLRs expressed by keratinocytes and melanocytes. Non-melanoma skin cancer (NMSC) consists 
of basal cell carcinoma (BCC) and SCC and represents the most frequent cancer in Caucasians, 
with continuing increase in incidence worldwide. The surgery is the most common treatment to 
remove clear margins of SCCs. However, in the case of recurring or irregular lesions there is the 
need of alternative strategies
115
.  
Differently from transplantation models in which the cancer immunity step has been by-passed, 
DMBA/TPA-induced skin cancer represents one of the best murine models of multi-step 
chemical carcinogenesis which studies SCC from the first stages of carcinogenesis, as discussed 
above. Initiation is an irreversible mechanism, which occurs following a single dose of a 
carcinogen, the polycyclic aromatic hydrocarbon, DMBA, which mutates Hras1 gene at the 
codon 61 (A to G). Mutations in Ras gene have been identified in 20% of skin cancers but also in 
several human epithelial cancers, like pancreatic (90%), colorectal (50%) and lung cancer 
(25%)
116
. Moreover, repeated treatments with TPA promote the expansion of initiated cells, 
predominantly keratinocyte stem cells, by activating inflammatory pathways such as EGFR, 
MAPK, STAT3 and PKC, and stimulating growth factor and ROS release. The two-step skin 
carcinogenesis is a good model to study human cancer because people are daily exposed to 
several low doses of both initiators and tumor-promoting agents
117
. The promotion brings to 
epidermal hyperplasia and, subsequently, papilloma formation (characterized by hyperplastic 
epidermis with a stromal core), which can also regress. Papilloma growth is expected within 8-
20 weeks of progression for the majority of murine strains
117
 (Fig. 11).  
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Fig. 11. Two-stage model of skin carcinogenesis in mice. During initiation, topical application of a sub-
carcinogenic dose of a mutating agent, DMBA, induces mutations basically keratinocyte stem cells in ras gene. 
Topical application of a promoting agent, TPA, continues for the duration of the study. However, the number of 
applications depends on the strain. Papillomas begin to arise after approximately 6–12 weeks of promotion and a 
fraction begin to convert to SCC after approximately 20 weeks. Representative H&E stained sections of normal 
skin, hyperplastic skin, a papilloma, and a SCC are presented. 
From Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications. E. L. Abel et al.; Nat. 
Protoc. 2011. 
 
 
It has been described that p53 gene mutations and trisomy of chromosomes 6 and 7 promote 
papilloma conversion to SCC. The incidence of carcinoma changes among different strains and 
depends on genetic background, the dose and the number of TPA treatments
117
. Histologic 
changes, described above for murine skin carcinogenesis, have been shown to occur 
concomitantly with modifications in the expression profile of specific keratin proteins. For 
example, keratin 14 (K14) and keratin 5 (K5) are principally expressed by proliferative basal 
cells of the epidermis. When keratinocytes differentiate and migrate to the suprabasal layer of the 
epidermis, they lose the proliferative marker, such as K14 and K5, while the expression of 
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keratin 1 (K1) and keratin 10 (K10), increases. Loss of K1 and K10 expression, together with 
high level of K5 and K14, are representative of the progression from murine skin papilloma to 
SCC and can be detected to verify the grade of the lesion
117
.  
 
The use of immune-deficient mice has been instrumental to define the specific contribution of 
signalling pathways, as well as of immune cells, in the model of DMBA/TPA. Among the 
transcription factors, which regulate cytokine and chemokine expression, NF-κB represents one 
the most important factor involved in cancer-related inflammation (CRI), as discussed above. In 
the skin, the innate immune system orchestrates strongly NF-κB activation. Ligands of TLR/IL-
1R superfamily promote the recruitment of MyD88 (except for TLR3), which leads to NF-κB 
activation
14
. MyD88 is involved in mechanisms of intrinsic and extrinsic CRI. Oncogenic 
mutations affecting MYD88 have been discovered in human B cell lymphoma
118
. MyD88 
contributed to extrinsic mechanisms of CRI in murine model of DEN-induced hepatocarcinoma, 
3-MCA-induced sarcoma and KRAS
G12D
-induced pancreatic carcinoma. However, it played a 
protective role in leukemic virus infections and in AOM/DSS-induced colon carcinogenesis, 
favoring the IL-18R pathway
119
. 
Trinchieri et al. have shown that MyD88-deficient mice were protected in DMBA/TPA-induced 
skin cancer in term of papilloma number and incidence. BM chimeras indicated the contribution 
of MyD88 from both hematopoietic cells and keratinocytes to promote carcinogenesis. 
Furthermore, also Il1r
-/-
 mice developed less papillomas compared to WT, even if the papilloma 
incidence did not change. In addition, tumor growth did not modify after the injection of ras-
mutated keratinocytes Il1r KO and WT, respectively. These data indicated that additional factors 
contribute to the protective phenotype of MyD88 KO mice.  
The authors have demonstrated that the keratinocyte expression of pro-tumorigenic factors, such 
as KC, GM-CSF, TNF, MMP9, and CXCR2 ligands, required the activation of the, IL-1α-
mediated, IL1R-MyD88-NF-κB pathway.  
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MyD88 and Il1r deficiency did not impair keratinocyte proliferation (in term of MAPK 
activation) but contributed to alter differentiation marker such as K1 and K10.  
The authors have explained a mechanism in which RAS-EGFR induction promoted the release 
of IL-1α by keratinocytes. IL-1α, in turn, activated IL1R-MyD88-NF-κB pathway favoring 
downstream the production of CXCR2 ligands and the inhibition of keratinocyte 
differentiation
116
. These data provide the pro-tumorigenic role of IL-1α and MyD88 in murine 
SCC.  
Mittal et al. have analysed the contribution of different TLRs that are upstream of MyD88. They 
showed that TLR4, but not TLR2 or TLR9, was involved in tumor development. Tlr4 KO mice 
showed resistance to tumor induction; the number of papillomas and the carcinoma incidence 
were significantly lower in Tlr4 KO than WT mice. In addition, Tlr4 deficiency was associated 
with lower levels of inflammatory mediators, like IL-6, IL-17 and IL-1β and granulocyte 
infiltration. TLR4 expression by both BM and stromal cells was required for carcinoma 
development in WT mice. Moreover, treatment with ethanol or LPS-binding antibiotic, to 
inactivate cutaneous bacteria-derived LPS did not change the inflammatory response of WT 
mice. The authors have identified the endogenous ligand HMGB1, released by necrotic and 
inflammatory cells, and not skin-colonizing bacteria-derived LPS, as the trigger of TLR4 that 
was responsible for the recruitment of neutrophils and the generation of a pro-tumorigenic 
inflammatory response
120
.  
Despite the role of NF-κB signalling in inflammation associated tumor development, several 
reports attest the importance of Stat-3 activation to enhance skin tumorigenesis. Stat3 activation, 
mediated by IL-6, IL-23 and growth factors, promoted the transcription of mitogenic and anti-
apoptotic genes such as cyclin D1 and bcl-xl in epithelial cells. Stat-3 favored the transcription of 
IL-23 while inhibited IL-12 in myeloid cells. IL-23 and IL-12 are members of the same family, 
produced by phagocytes and DCs. Several data also reported IL-23 production by tumor-
associated myeloid cells
121,30
. It has been demonstrated that, although they shared a common 
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subunit, IL-23 and IL-12 played opposing role in CRI. While IL-12 promoted an anti-tumor IFN-
γ-dependent Th1 response, through Stat-1 signalling, IL-23 induced the expansion of Th17 cells 
through Stat-3 activation. Grivennikov et al. have demonstrated that samples of murine and 
human CRC displayed high mRNA levels of both IL-23 and IL-17A. IL-23 ablation in the 
haematopoietic compartment reduced tumor multiplicity, Stat3 phosphorylation, IL-22, IL-6 and 
IL-17A production in murine CRC. Depletion of intestinal microbiota and TLR/MyD88 
inactivation reduced IL-23 expression, Stat3 phosphorylation and IL-17A production. These data 
underline that genetic mutations can cause epithelial barrier alterations with the entry of bacteria, 
which activate IL-23/IL-17-mediated adenoma growth in mice
31
. 
Moreover, Langowski et al. have shown the resistance of Il23 KO mice in the model of 
DMBA/TPA-induced skin cancer. The authors attributed the protective phenotype of Il23 
deficient mice to the higher level of CTLs coincident with lower production of angiogenic 
factors, such as IL-17 and MMP-9
30
. Despite the tumor-promoting role of IL-23, as a driver of 
Th-17 cell differentiation and regulator of adaptive immunity, Teng et al. have described that IL-
23 antagonized antitumor immune response also blocking NK activity (perforine release and 
IFNg antitumor effect) through an unknown mechanism, in lung metastasis and 3-MCA-induced 
fibrosarcoma
29
. 
Moreover, several papers attest the pro-tumorigenic role of IL-17 in skin cancer. Wang et al. 
have demonstrated that Il17
-/-
 mice were strongly resistant to DMBA/TPA skin cancer. CD4
+ 
T 
cells are the major source of IL-17. IL-17 deficiency was associated to lower IL-6 production 
and consequently p-Stat3 activity (regulation of proliferative and anti-apoptotic pathways) with 
reduced myeloid recruitment in the tumor microenvironment
121
. IL-17 neutralization, in mice 
with DMBA-induced papilloma, reduced tumor-progression
31
.  
Based on the knowledge obtained in literature, the two-step model of DMBA/TPA represents the 
best instrument, which mimics the development of SCC in mice. The use of immune-deficient 
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mice has been crucial to define the specific contribution of signalling pathways, like IL1R-
MyD88-NF-κB and IL-23/IL17-pStat3, as well as of myeloid cells, such as granulocytes in CRI. 
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2 The long pentraxin PTX3 as a key component of humoral innate immunity and     
inflammation 
 
2.1 Gene organization, protein structure and expression 
Pentraxins are essential components of the innate immunity, which are highly conserved from 
arachnids to humans. They represent a superfamily of acute phase protein divided in long and 
short pentraxin on the bases of the primary structure. C-reactive protein (CRP) and serum 
amyloid P (SAP) components are classic short pentraxins produced by human and murine 
hepatocytes, respectively. Thereby, the long pentraxin PTX3 is a multimeric glycoprotein of 381 
amino acids, which shares the C-terminal pentraxin domain with the short pentraxin and it is 
coupled with a unique N-terminal region. The primary sequence of PTX3 is highly conserved 
during evolution with 82% of identical amino acids and 92% of conserved amino acids between 
human and mouse
122
. However, PTX3 has a unique quaternary structure with eight subunits, 
assembled together to form an octamer by covalent interactions between cysteines of both N-
terminal and C-terminal domain, respectively. Only SAP from Limus polyphemus folds into an 
octamer. It has been described a single N-glycosylation at Asn220 of the C-terminal domain 
which is involved in the binding to several ligands such as ficolin-1 and P-selectin
123,124
 (see 
below). 
The human and murine PTX3 gene localizes on chromosome 3 and is organized in three exons. 
The first two exons code for the leader peptide and the N-terminal domain, respectively, while 
the third exon codes for the C-terminal pentraxin domain. The promoter of both human and 
murine PTX3 gene displays potential binding sites for many transcription factors such as Pu1, 
AP-1, NF-κB, Sp-1 and NF-IL-6123. The soluble pattern recognition molecule (PRM) PTX3 has 
been discovered as a cytokine-inducing gene in fibroblasts and endothelial cells
125
. In fact, while 
AP-1 regulated PTX3 basal expression, TNF-α and IL-1β promoted PTX3 transcription through 
NF-κB activation. In addition, TNF-stimulation favored PTX3 production through JNK pathway 
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in alveolar epithelial cells, while high-density lipoproteins (HDLs) activated PI3K/Akt axis in 
endothelial cells. Moreover, HIF-1α and IL-1R/MyD88 were involved in the up-regulation of 
PTX3 gene expression in cardiac ischemia reperfusion in human and mouse, respectively126. 
Furthermore, it has been published recently that TLR4/MyD88 pathway controlled PTX3 
production in uroepithelial cells during urinary tract infection (UTI)
127
.  
PTX3 is expressed by a variety of cell types (e.g. DCs, monocytes, macrophages, alveolar 
epithelial cells, uroepithelial cells, mammary epithelial cells, smooth muscles cells, endothelial 
cells, fibroblasts, chondrocytes and adipocytes), except lymphocytes, upon exposure to 
inflammatory signals like TNF-α, IL-1β, TLR agonists and HDLs, microbial moieties (e.g. LPS, 
OmpA) or pathogens. Results showed that IFN-γ inhibited the production of PTX3 by DCs, 
monocytes and macrophages, while IL-10 amplified PTX3 induction by LPS. It has been 
described that glucocorticoid hormones modulated PTX3 production in a cell-dependent manner, 
favoring the production in stromal cells while exerting an inhibitory effect in DCs and 
macrophages
128
 (Fig. 12). Moreover, Jaillon et al. have demonstrated that neutrophil granules 
showed a reservoir of the long pentraxin. Upon microbial recognition and inflammatory signals, 
PTX3 was released from the granules and localized in NETs. Given the abundance of circulating 
neutrophils, they represent the major source of PTX3, ready-to-use
129
.  
The great conservation of both PTX3 sequence and regulation between human and mouse allows 
the use of PTX3-deficient mice to address its role especially in host defence and sterile 
inflammation. 
 
2.2 PTX3 in host defence 
The first function reported for PTX3 was the ability to bind a broad spectrum of microorganisms, 
including Aspergillus fumigatus conidia, bacteria such as Pseudomonas aeruginosa, Klebsiella 
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pneumoniae and Uropathogenic Escherichia Coli133 (UPEC), viruses like human and murine 
cytomegalovirus (MCMV) and selected strains of influenza virus
122
. As suggested, PTX3-
deficient mice have lead to investigate the in vivo functions of PTX3 in host defence. 
Interestingly, Ptx3
-/- 
mice displayed increased susceptibility to invasive pulmonary aspergillosis, 
showing higher mortality than Ptx3
+/+
 mice. PTX3-deficiency was associated with defective 
recognition of conidia by alveolar macrophages and DC, as well as defective induction of a 
protective Th1 response
130
. Moreover, treatment with recombinant PTX3 (r-PTX3) reverted the 
Ptx3
-/- 
mice phenotype in a murine model of aspergillosis
131
. Other studies conducted by Diniz et 
al. have shown that zymosan recognition, mediated by PTX3, enhanced dectin-1-dependent 
phagocytosis mediated by macrophages
132
. Moalli et al. have demonstrated that the PTX3 N-
terminal domain was responsible for conidia recognition, but the full-length molecule was 
necessary for opsonic activity. In the presence of C3-deficient serum or anti CR3/CD11b the 
amplification of phagocytosis, mediated by PTX3, was abrogated. Under these experimental 
conditions, C3 represented the most potent opsonin, which activated CR3 on neutrophil surface. 
The presence of PTX3-opsonized conidia enhanced CD11b activation inside the cell, in the 
phagocytic cup. In addition, PTX3 bound FCγRII/CD32 favoring its activity. FCγRII, in turn, 
promoted the translocation of CD11b to the phagocytic cap. PTX3-opsonized conidia enhanced 
neutrophil phagocytic activity through FCγR-dependent CR3 translocation to the phagocytic 
cap
133
. Other results indicated that PTX3 also displayed therapeutic activity in chronic lung 
infections by P. aeruginosa, the major cause of morbidity in Cystic Fibrosis patients. Mice 
infected chronically with P. aeruginosa and treated with human r-PTX3 presented an enhanced 
clearance of bacteria in the lungs.  
PTX3 recognizes the outer membrane protein (OmpA) of K. pneumonia and amplifies the 
inflammatory response
134
. Recently, Jaillon et al. have demonstrated the protective role of PTX3 
in UTI driven by UPEC. PTX3 expressed by leukocytes and uroephitelial cells interacted with 
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UPEC and promoted the clearance mediated by phagocytes. PTX3-deficient mice displayed an 
exacerbated UTI. PTX3 represents a good marker of severity of infection suggesting its 
relevance in the control of infection in humans. In addition, polymorphisms in PTX3 gene were 
associated with higher incidence of cystitis and acute pyelonephritis
133
.  
Several experiments have also highlighted the role of PTX3 in viral infections. For instance, 
PTX3 bound both human and murine MCMV reducing viral entry in DCs. Consistently Ptx3
-/-
 
mice were more susceptible to MCMV infection than Ptx3
+/+
 mice. Human and murine PTX3 
also bound influenza virus (H3N2), through sialic acid, and mediated the inhibition of 
haemagglutination. PTX3-deficient mice were more susceptible than Ptx3
+/+
 mice to H3N2 
infection. Since a single amino acid substitution in the haemagglutinin of H3N2 prevented PTX3 
binding, it is evident that PTX3 binds selected microorganisms with high specificity
135
.  
The relevance in humans of the data, which come from animal models of infection, has been 
demonstrated studying polymorphisms of PTX3 gene. For example, the homozygous haplotype 
(h2/h2) in PTX3 was related with an increased risk of A. fumigatus infection as well as with 
defective expression of PTX3. Functionally, PTX3-deficiency in h2/h2 neutrophils, led to 
defective phagocytosis and clearance of the fungus
136
.  
 
2.3 PTX3 in angiogenesis and matrix remodelling 
Angiogenesis is the process, which generates new blood vessels and occurs during physiologic 
conditions, such as growth, embryonic development and menstrual cycle. However, uncontrolled 
neovascularization arises during tumor growth. It has been described the existence of pro and 
anti-angiogenic factors, which controlled the balance of neovascularization. For instance, 
fibroblast growth factor 2 (FGF2) is a pro-angiogenic factor, which interacts with tyrosine kinase 
FGFR and heparan sulphate proteoglycans and regulates both endothelial cell proliferation and 
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chemotaxis in vitro and angiogenesis, during tumor progression, in vivo137. Rusnati et al. have 
shown that the N-terminal domain of PTX3 contained two binding sites for FGF2. PTX3 
prevented FGF2 binding to endothelial cell receptors, leading to specific inhibition of FGF2-
induced proliferation and to motogenic activity of endothelial cells in vitro. PTX3 cDNA 
transduction in FGF2-overexpressing murine aortic endothelial (FGF2-T-MAE) cell line 
inhibited their capacity to generate vascular lesions when transplanted in mice
138,139
. Margheri at 
al. have demonstrated that the injection of PTX3-transfected breast cancer cells caused a 
reduction in angiogenesis, compared to non-transfected cells, as a result of FGF2 inhibition
140
. 
Furthermore, as shown by Presta et al., PTX3 inhibited the mitogenic activity of murine 
TRAMP-C2 and human prostate cancer cells after stimulation with FGF2, FGF8 or testosterone 
in vitro. In addition, hPTX3 overexpression in TRAMP-C2 cell line, grafted subcutaneously in 
syngeneic mice, was associated with a reduction of tumor weight, cyclin D1 proliferation and 
CD31 expression compared to the injection of mock_TRAMP-C2 cell line. These data confirm 
that hPTX3 also affects the FGF/FGFR angiogenic pathway in vivo141. 
It has been demonstrated that the binding of FGF2 to tyrosine kinase receptor favored the 
proliferation and migration of human coronary artery smooth muscle cells, contributing to the 
process of restenosis that follows the angioplasty. The PTX3-FGF2 interaction impaired smooth 
muscle cell proliferation during restenosis. Consistently, a single local endovascular injection of 
AAV-PTX3 inhibited intimal hyperplasia after arterial injury in rats
142
.  
Salustri et al. have shown that PTX3 localized within the hyaluronan (HA)-rich matrix formed 
around the oocyte in the cumulus oophorus complex. PTX3 interacted with TSG-6 and inter-α-
trypsin inhibitor (IαI), two molecules required for effective incorporation of the newly 
synthesized HA into the matrix, an essential step for the stabilization and organization of the 
matrix of cumuli. As a consequence, Ptx3
-/- 
mice presented a severe deficiency in female fertility 
because of defective assembly of the cumulus matrix
143
.  
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These results provide strong evidence regarding the involvement of PTX3 in the process of 
angiogenesis and matrix remodelling. Since neovascularization and extracellular matrix 
modifications occur during tumor growth, these data also anticipate the involvement of PTX3 in 
the context of cancer immunology (discussed in the next chapter). 
 
Fig. 12. PTX3: cellular sources and functions. PTX3 is an essential humoral component of innate immunity 
produced by leukocytes and stromal cells in response to TLR-agonists or pro-inflammatory stimuli such as IL-1β 
and TNF-α. PTX3 is a functional ancestor of antibodies and acts as opsonin against specific pathogens including 
UPEC, A. fumigatus and P. aeruginosa. PTX3 is involved in matrix deposition and fertility, favoring HA 
organization, and in angogenesis, inhibiting FGF-2 and FGF-8b activity. Then, PTX3 regulates inflammation 
basically modulating complement cascade and P-selectin dependent leukocyte recruitment.  
From S. Jaillon et al.; The long pentraxin PTX3 as a key component of humoral innate immunity and a candidate 
diagnostic for inflammatory diseases. International Archives of Allergy and Immunology. 2014. 
 
2.4 PTX3 in inflammation: regulation of complement activation and P-selectin dependent 
leukocyte recruitment 
The first ligand described for PTX3 was the complement component C1q, the main actor of the 
classical complement pathway activation. The interaction between PTX3 and C1q occurred in 
calcium independent manner and led to a dual effect on complement activation depending on the 
way in which the binging occurred. In fact, the interaction between C1q and plastic-immobilized 
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PTX3 induced the activation of the classical complement cascade and the deposition of C3 and 
C4. In contrast, when the interaction occurred in fluid phase, PTX3 inhibited the activation of the 
classical complement cascade blocking functional sites of C1q
144
.  
In addition, it has been demonstrated PTX3 interaction with three members of the lectin 
pathway: ficolin-1/M, ficolin-2/L and mannose-binding lectin (MBL). In the case of A. 
fumigatus or Candida Albicans infection, PTX3 enhanced the deposition of ficolin-2 or MBL, 
respectively, on pathogen surface, promoting complement activation
145,146
. PTX3 promoted the 
binding of Ficolin-1 to late apoptotic or necrotic Jurkat T-cells and favored phagocytosis by 
human macrophages
147
. These results suggest that during microbial infections PTX3 enhances 
complement activation favoring the resolution of the disease.  
Moreover, Deban et al. have also shown the involvement of PTX3 in the regulation of the 
alternative pathway. The authors have discovered two binding sites for FH in N-terminal portion 
and glycosylated pentraxin domain of PTX3. As discussed before, FH is a soluble regulator of 
the alternative pathway, which inhibits complement activation in different ways such as acting as 
cofactor of FI, inhibiting the assembly of FB to C3b or promoting C3 convertase decay. PTX3-
bound FH remained functionally active
148
.  
Recently, PTX3 has been showed to interact also with a soluble inhibitor of both classical and 
lectin pathway, C4b-binding protein (C4BP) in a calcium dependent manner. C4BP inhibits the 
complement activation acting as cofactor of FI, inactivating C4d, and promoting C3 convertase 
decay. PTX3-bound C4BP maintained its activity, as described for FH. In addition, when PTX3 
bound the extracellular matrix (fibroblast- or endothelial cell-derived) significantly increased the 
binding of C4BP. PTX3 enhanced the binding of C4BP to apoptotic cell surface limiting 
complement activation and an exacerbated inflammatory response
149
. In models of sterile 
inflammation, such as the murine model of myocardial infarction, caused by coronary artery 
ligation and reperfusion, PTX3 played a protective role limiting an exaggerated inflammatory 
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response. In fact, Ptx3
-/-
 ischemic lesions displayed higher myocardial damage, neutrophil 
infiltration and C3 deposition than Ptx3
+/+
, likely through the missing interaction of PTX3 with 
FH
150
.  
 
 
Fig. 13. Roles of PTX3 in the initiation and regulation of the Complement cascade. PTX3 participates in the 
activation and regulation of Complement cascade through the three pathways, by interacting with C1q, lectins, and 
with factor H or C4BP. PTX3 plays a complex role in removal of pathogens or dying cells via classical Complement 
activation. The classical and the lectin pathways are initiated when PTX3 binds to the activation structure (e.g., 
antigens or microbial moieties). Upon this interaction, downstream Complement components are activated. On the 
handling of apoptotic cells, the effect of PTX3 on Complement could be divergent depending on the experimental 
setting (fluid phase or solid phase, in vitro or in vivo). Interestingly, PTX3 interacts with soluble Complement 
regulators factor H and C4BP, limiting the activation of the terminal pathway and hence Complement mediated 
excessive inflammation.  
From: A. Inforzato et al.; PTX3 as a paradigm for the interaction of pentraxins with the complement system. 
Seminar in Immunology. 2013. 
 
In sterile inflammation, like myocardial stroke, PTX3 avoids an exacerbated complement-
mediated inflammatory response, preventing tissue damage (Fig. 13). 
Another mechanism through which PTX3 regulates inflammation derived from the interaction 
with P-selectin. After inflammatory stimuli, P-selectin, expressed by endothelial cells and 
platelets, binds P-selectin glycoprotein 1 (PSGL-1) on leukocyte surface. This interaction 
promotes the rolling of leukocytes on endothelium and their migration to the site of 
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inflammation. Deban et al. have shown that hPTX3 selectively bound P-selectin and not E- or L-
selectin, through the glycosidic moiety of the pentraxin domain and competed with the leukocyte 
PSGL-1 in vitro. In vivo analysis of leukocyte rolling, after thrombin-mediated vessel 
stimulation, showed that Ptx3
-/-
 mice displayed higher leukocyte rolling compared to Ptx3
+/+
 
mice. Moreover, in a murine model of pleurisy, followed by KC injection, PTX3 administration 
reduced the accumulation of neutrophils in the pleural cavity.  
 
 
Fig. 14. PTX3 regulates inflammation through the modulation of P-selectin dependent neutrophil 
recruitment. Interactions of PSGL-1, on neutrophils, with P-selectin, on activated endothelial cells, mediate 
leukocyte rolling and recruitment at sites of inflammation. Rolling neutrophils release PTX3 from specific granules. 
It has been demonstrated that PTX3 binds to locally expressed P-selectin, which prevents subsequent interactions 
with PSGL-1 in murine models of acute lung injury, pleurisy and acute kidney injury. As result, PTX3 avoids an 
exacerbated inflammatory response limiting neutrophil recruitment to the site of inflammation.  
From: L. Deban, et al.; Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat immunol. 2010. 
 
 
A similar inhibitory effect has been observed blocking P-selectin. Similar results have been 
obtained in a murine model of acute lung injury (ALI) and post-ischemic acute kidney injury 
where the recruitment of neutrophils was a key event to develop the respiratory or renal 
damage
151,152 
(Fig. 14).  
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All these data indicate a mechanism in which, PTX3, released mainly by neutrophils, acts as 
negative feedback and prevents an exacerbated neutrophil recruitment blocking the interaction P-
selectin-PSGL-1.  
Together these results highlight the role of PTX3 in the resolution of microbial infections acting 
as an opsonin and favoring complement activation. In contrast, PTX3 dampens inflammatory 
response and tissue damage in sterile condition, limiting complement activation, favoring FH 
activity, and reducing P-selectin-dependent neutrophil recruitment. 
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3 Role of PTX3 in cancer 
3.1 PTX3 as a tumor biomarker and onco-suppressor gene 
A large number of data suggested the role of PTX3 as a marker of inflammation. It has been 
shown that PTX3 blood levels increased rapidly and dramatically during infectious diseases, 
including Mycobacterium tuberculosis and Neisseria meningitidis infections, or vascular 
diseases such as acute myocardial infarction
153,154,155
.  
Recently, some papers indicated its relevance as marker of CRI. For example, Planque et al. have 
validated PTX3 as a novel lung cancer biomarker in the serum of patients (median value of 4,91 
ng/ml compared to 1,52 ng/ml of healthy donors)
156
. Moreover, Locatelli et al. have shown 
PTX3 immunoreactivity in high grade glioblastoma tissues, close to the vessel network and in 
the extracellular matrix, even if it was absent in many astrocytoma tissues
157
. Recently, data from 
Gene Expression Omnibus (GEO) have indicated higher expression level of PTX3 mRNA in 
bone metastatis of breast cancer patients compared to other metastatic sites
158
. In contrast, data 
from Oncomine database indicated that PTX3 mRNA expression is significantly downregulated 
in several prostatic cancers. Accordingly, Presta et al. have investigated PTX3 expression in 33 
prostate adenocarcinoma patients. Immunohistochemistry for PTX3 suggested that the positivity 
correlated with non-tumor parenchyma or with the extracellular spaces of invasive tumors, 
around vessels. These data, together with the anti-angiogenic role of PTX3 in murine and human 
prostatic cancer cell lines, suggested an antineoplastic activity of PTX3 in prostate cancer
141
. 
Studies in esophageal squamous cell carcinoma (ESCC) have shown that PTX3 promoter was 
epigenetically silenced by hypermethylation and PTX3 expression was inhibited compared to 
adjacent non-tumor tissue. Methylation of the PTX3 promoter was an early event in tumor 
development that may be used as biomarker for ESCC diagnosis
159
.  
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Unpublished data from our laboratory indicated that PTX3 was methylated in selected 
mesenchymal and epithelial cancers such as leiomyosarcoma, SCC and CRC.  
All these data indicate that PTX3, in addition to act as a biomarker of CRI in specific tumors, 
can be express possibly by infiltrating leukocytes or vessels in the tumor microenvironment. 
However, PTX3 is silenced in selected mesenchymal and epithelial tumors acting as an extrinsic 
oncosuppressor gene (see below).  
 
3.2 PTX3-deficiency is associated with increased tumour growth in a murine model of 
fibrosarcoma chemically induced by 3-methylcolantrene (3-MCA) 
Unpublished experiments from our group demonstrated the protective role of PTX3 in a murine 
model of 3-MCA-induced fibrosarcoma. These experiments showed that PTX3-deficiency was 
associated to increased fibrosarcoma incidence (Fig. 15).  
 
 
 
Fig. 15 - PTX3-deficiency increases susceptibility to carcinogenesis. 
Incidence (A) and tumor volume (B) of 3-MCA-induced sarcoma in Ptx3
-/-
 and Ptx3
+/+
mice. In B, the volume of 
each tumor is shown. One experiment with 20 mice/group out of 10 performed with similar results is shown. ***: 
p<0.001, paired Student's t test. Adapted from Bonavita, Gentile et. al., in press. Cell. 
 
 
A B 
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Moreover, Ptx3
-/-
 sarcomas grew faster and reached the end point earlier than control mice. 
Rescue experiments performed by administering rPTX3, throughout the duration of the 
experiment, significantly reduced the tumor incidence, macrophage infiltration, angiogenesis and 
C3 deposition of Ptx3
-/-
 mice.  
During early carcinogenesis macrophages were the primary source of PTX3 in both 3-MCA-
injection site and liver. Lower circulating PTX3 levels in Il1r1
-/-
 mice compared to Ptx3
+/+
 mice 
indicated the involvement of IL-1 in PTX3 production. In 3-MCA tumors, PTX3 expression was 
low and associated to vessels, infiltrating macrophages and neutrophils, whereas tumor cells 
expressed variable levels of PTX3. Studies with chimeric mice demonstrated that there were no 
differences in term of fibrosarcoma incidence between Ptx3
+/+
 receiving Ptx3
-/-
 BM and vice 
versa, suggesting the importance of both hematopoietic and non-hematopoietic cells as source of 
PTX3 to give protection.  
The biochemical and histological analysis of the injection site showed the association between 
PTX3-deficiency and increased inflammation in terms of higher leukocyte recruitment at the 
injection site and pro-inflammatory mediators such as CCL2 and CXCL2. Higher macrophage 
and monocyte infiltration and angiogenesis (CD31
+
 expression) were observed in Ptx3
-/-
 than 
Ptx3
+/+
 tumors (Fig. 16).  
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Fig. 16. (A) Analysis of macrophages (F4/80
+
 immunoreactive area, IRA) and (B) angiogenesis (CD31
+
 IRA) in 3-
MCA-sarcoma by immunohistochemistry (each dot represents the average of ten fields, mean ± SEM). *: p<0.05, 
unpaired Student's t test. Adapted from Bonavita, Gentile et. al., in press. Cell. 
  
Confocal microscopy displayed that PTX3-deficiency was associated with increased complement 
activation, in terms of higher C3 and lower FH deposition (Fig. 17A-C). In Ptx3
+/+
 sarcomas, 
PTX3 and C3 were inversely correlated, whereas PTX3 and FH showed a positive correlation.  
In the effort to assess the pathogenic role of increased complement activation associated to 
PTX3-deficiency, the susceptibility to 3-MCA of C3-deficient and PTX3/C3-double deficient 
mice was evaluated. The deficiency of C3 reduced sarcoma incidence of Ptx3
-/-
 mice to the level 
of Ptx3
+/+
 mice (Fig. 17D) and abolished macrophage accumulation of Ptx3
-/-
 tumors.  
 
A B 
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Fig. 17. PTX3-deficiency is associated to increased Complement deposition in 3-MCA-sarcoma. 
(A, B): Analysis by confocal microscopy of C3 deposition in the injection site (*) at 7 days (A) or in tumors (B) of 
Ptx3
-/-
 and Ptx3
+/+
 mice. (C) Analysis by confocal microscopy of Factor H in 3-MCA-tumors. *: p<0.05, **: p<0.01, 
unpaired Student's t test. Each dot represents the average of mean fluorescence intensity of ten regions of interest 
(ROI) per tumor. Scale bars represent 150µm. (D) Incidence of 3-MCA-sarcoma in C3
-/-
 and/or Ptx3
-/-
 and Ptx3
+/+
 
mice (n=10-15). ***: p<0.001, paired Student's t test. Adapted from Bonavita, Gentile et. al., in press. Cell. 
 
    
 
In addition, treatment with a C5aR antagonist (PMX53), throughout the duration of the 
experiment, rescued the phenotype of Ptx3
-/-
 mice. These data indicated that PTX3-deficiency 
led to complement activation, in term of C3 and C5a activation and it caused increased 
susceptibility to 3-MCA.  
In vitro assay suggested that C3 deposition was higher in Ptx3-/- than Ptx3+/+ fibrosarcoma cells. 
Moreover, rPTX3 reduced C3 levels on Ptx3
-/- 
cells. In addition, a FH inhibitor, which inhibited 
the binding of PTX3 to the FH, increased C3 deposition on Ptx3
+/+
 cells whereas did not further 
influence C3 deposition on Ptx3
-/- 
cells. Interestingly, FH inhibitor abolished the effect of rPTX3 
on Ptx3
-/- 
cells, favoring C3 increase. All together these results demonstrated that complement is 
A B 
C D 
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an essential component of tumor-promoting inflammation and that the lack of PTX3-mediated 
FH recruitment is responsible for the higher complement activation of Ptx3
-/-
 tumors.  
PTX3-deficiency was associated with increased macrophage infiltration and higher levels of the 
monocyte attracting chemokine CCL2. Complement activation and C5a in particular favor 
chemokine production. It was therefore important to assess the relevance of CCL2 in the 
enhanced susceptibility to carcinogenesis exhibited by PTX3-deficient mice. CCL2 blocking for 
the duration of carcinogenesis reverted fibrosarcoma incidence of Ptx3
-/-
 mice suggesting that the 
treatment was effective in condition of exacerbated CCL2 production (Fig. 18).  
 
 
 
 
Fig. 18. Role of CCL2 in carcinogenesis and TAM polarization in PTX3-deficient mice. Incidence of 3-MCA-
sarcoma in Ptx3
-/-
 and Ptx3
+/+
 mice treated with anti-CCL2, or irrelevant mAb (n=9-11) (100µg/mouse three 
times/week) for the duration of the experiment. ***: p<0.001, paired Student's t test.  
Adapted from Bonavita, Gentile et. al., in press. Cell. 
 
 
Since CCL2 has been shown to skew macrophage polarization in an M2-like direction the 
phenotype of TAM was characterized. Both MHC II 
high
 and MHC II 
low
 TAMs from Ptx3
-/-
 mice 
showed an M2-like phenotype and high level of iNOS. 
CRI is potentially a cause of gene instability. Accordingly it was addressed whether the 
increased tumor incidence observed in Ptx3
-/-
 mice was associated to increased 3-MCA induced 
gene mutation. Ptx3
-/-
 tumors were associated to increased p53 mutations, compared to Ptx3
+/+
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tumors. In addition, PTX3-deficiency correlated with higher expression of 3-MCA extra-
mutations such as  8-OH-deoxiguanosine (8-OH-dG), ROS/RNS-associated DNA damage, or 
DDR markers such as 53BPI or H2Ax, compared to Ptx3
+/+
 tissues in early carcinogenesis. 
Moreover, treatments with aminoguanidine hemisulphate (AG), an irreversible inhibitor of 
iNOS, in 3-MCA injected mice, reduced the fibrosarcoma incidence of Ptx3
-/-
 mice but also the 
expression of DDR or ROS/RNS markers. These results suggest that increased CRI in PTX3-
deficient mice is associated with increased genetic instability as assessed by the frequency of 
Trp53 mutations, oxidative DNA damage and expression of DDR markers.  
These results demonstrated for the first time that the regulatory component of the humoral arm of 
innate immunity, PTX3, acts as an extrinsic oncosuppressor gene in mice in a model of 
chemically induced mesenchymal tumor. In addition the epigenetic studies discussed above 
demonstrate that PTX3 gene is silenced by hypermethylation in selected human tumors. 
Adapted from Bonavita, Gentile et. al., in press. Cell. 
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Aim  
Since previous studies by our group demonstrated the protective role of PTX3 in cancer-related 
inflammation (CRI) in a murine model of chemically induced fibrosarcoma, a tumor with 
mesenchymal origin, we also addressed the role of PTX3 in a murine model of epithelial origin, 
DMBA/TPA chemically induced skin cancer.  
Beyond the effect exerted on macrophages and complement components, we investigated other 
potential PTX3-related mechanisms in dampening tumor-promoting inflammation in mouse skin 
carcinogenesis. 
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4 Results 
4.1 PTX3 is produced during skin carcinogenesis 
DMBA is a carcinogenic compound acting as initiator in a single cutaneous application, while 
TPA is a promoter, applied three times weekly during all the period of carcinogenesis. We first 
analysed the production of PTX3 during DMBA/TPA-induced skin carcinogenesis. As shown in 
Fig. 19A, PTX3 was strongly produced in the skin 12h after a single DMBA-TPA treatment.  
 
Fig. 19. DMBA/TPA treatment induces PTX3 expression in both early and late carcinogenesis.  
(A) Immunohistochemical analysis for PTX3 on Ptx3
+/+
 skins collected 12 hours after the first TPA. One 
representative photograph of 6 skin sections is shown. (B) PTX3 dosage by ELISA of skin homogenates recovered 
12 hours after 1 or 5 TPA. *: p<0.05, unpaired Student's t test. (C) Immunohistochemical analysis for PTX3 on 
Ptx3
+/+
 papillomas recovered 24h after 16 weeks of DMBA/TPA treatments. (D) PTX3 dosage by ELISA of 
homogenized Ptx3
+/+
 papillomas. *: p<0.05, unpaired Student's t test. 
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ELISA confirmed significantly higher levels of PTX3, 12h after 1 or 5 TPA treatments, 
following DMBA application, in immunocompetent skins (Fig. 19B). In papillomas recovered 
24h after 16 weeks of DMBA/TPA treatments, PTX3 immunostaining was associated with the 
extracellular matrix (Fig. 19C) and PTX3 levels were higher than in control skins (Fig. 19D). 
Moreover, confocal microscopy of the skin revealed PTX3 association with infiltrating 
macrophages (Fig. 20A) and neutrophils (Fig. 20B and 20C) 8h after a single DMBA-TPA 
treatment and with lymphatic vessels 24h after 16 weeks of DMBA/TPA treatments (Fig. 20D). 
  
Fig. 20. PTX3 immunostaining is associated to infiltrating macrophages and neutrophils, lymphatic vessels 
and interstitial stroma. (A-C) Immunofluorescence analysis for PTX3 and F4/80 (macrophage marker) or for 
PTX3 and Ly6G (neutrophil marker) on skin samples, collected 8 hours after the first TPA. One representative 
figure shows the production of PTX3 (red) by infiltrating macrophages or neutrophils (green). (D) 
Immunofluorescence analysis for PTX3 and LYVE-1 (lymphatic marker)  on Ptx3
+/+
 papillomas collected after 16 
weeks of DMBA/TPA. One representative image displays the presence of PTX3 (red) in the extracellular matrix, 
and PTX3 association with lymphatic vessels (green). 
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Collectively, these results demonstrate that PTX3 is abundantly produced in early carcinogenesis 
by infiltrating leukocytes, vessels and interstitial stroma. Moreover, PTX3 is present in the 
extracellular matrix also in late carcinogenesis following chronic treatments with TPA.  
 
4.2 PTX3-deficiency is associated with increased incidence, mean number of papilloma and 
more aggressive lesions 
Ptx3
-/- 
and Ptx3
+/+
 mice on C57BL/6J background were compared for susceptibility to 25 μg 
DMBA initiation followed by 4 μg TPA, three times weekly, for 30 weeks of promotion. As 
shown in Fig. 21A, nearly 100% of Ptx3
-/- 
mice developed at least one papilloma in comparison 
to Ptx3
+/+
 mice with less than 80% of papilloma incidence (p=0.0004). Moreover, PTX3-
deficient mice were more susceptible to DMBA/TPA-induced skin carcinogenesis than Ptx3
+/+
 
controls also in term of papilloma number (p=0.0005)(Fig. 21B). 
 
 
Fig. 21.  PTX3 plays a protective role in DMBA/TPA-induced skin papillomas. (A) Percentage of papilloma 
incidence and (B) number of papillomas per mouse in each group (mean ± SEM). Groups of female Ptx3
+/+
 and 
Ptx3
-/- 
mice are treated with 25 μg DMBA, and 1 week later, three times weekly with 4 μg TPA for 30 weeks as 
described in Materials and Methods. Mice are monitored for skin papilloma development for 30 weeks. One 
experiment with 10 mice/group of 4 performed with similar results is shown. ***: p<0.001, paired Student's t test. 
Adapted from Bonavita, Gentile et. al., in press. Cell. 
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In addition, histological classification resulting by hematoxylin and eosin staining and certain 
macroscopic characteristics, such as tumors growing downward as well as tumors attached to the 
underlying muscle layer, showed higher carcinoma incidence of Ptx3
-/-
 lesions compared to 
competent mice (p=0.009) (Fig. 22A-D). In DMBA/TPA-induced skin carcinogenesis, 
histological changes occur concomitantly with modifications in the expression profile of specific 
keratin proteins. Keratinocytes differentiate and migrate to the suprabasal layer of the epidermis 
losing the proliferative marker K14 and acquiring the differentiation marker K1.  
Fig. 22. Ptx3
-/-
mice display higher carcinoma incidence compared to Ptx3
+/+
 mice. (A) Histological 
classification of lesions developed in PTX3-deficient and competent mice after 30 weeks of DMBA/TPA. ***: 
p<0.01, Chi-square test. (C, D) Two representative sections of Ptx3
-/-
 lesions. (D) One representative section of 
Ptx3
+/+
 lesions stained with hematoxylin and eosin.  
 
Loss of K1, together with high level of K14, are representative of the progression from murine 
skin papilloma to SCC and can be detected to verify the grade of the lesion
117
. Analysis of K1 
and K14 expression by confocal microscopy showed higher K14 expression level and lower K1 
intensity of Ptx3
-/- 
compared to Ptx3
+/+ 
lesions (Fig. 23A-D). All these data indicate that PTX3 is 
involved in controlling the incidence and number of papillomas and affects malignant 
progression from papilloma to SCC. Previous results showed the higher tumor susceptibility of 
Ptx3
-/-
 mice in a model of 3-MCA-induced fibrosarcoma. All these data suggest the protective 
role of PTX3 in both epithelial and mesenchymal tumors. 
Ptx3
+/+
  Ptx3
-/-
 
A B C D 
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Fig. 23. Expression profile of specific keratin proteins. Confocal microscopy for K14 (proliferative marker), K1 
(differentiation marker) and DAPI (nuclear marker) on PTX3-deficient and competent papillomas collected after 30 
weeks of DMBA/TPA. (A, B) Two representative images showing cutaneous K14 expression. (C, D) Two 
representative images showing cutaneous K1 expression in both Ptx3
+/+ 
and Ptx3
-/-
 lesions, respectively. 
 
4.3 PTX3-deficiency is associated with higher inflammation in early carcinogenesis 
The following experiments had the aim to explain the molecular mechanisms, which underlay 
the protective role of PTX3 in mouse skin carcinogenesis. The long pentraxin PTX3 is an 
essential component of the humoral arm of innate immunity, which regulates inflammation 
basically through three mechanisms. PTX3 activates and regulates the complement cascade, 
controls leukocyte recruitment in a P-selectin-dependent manner and interacts with FcγR miming 
antibody properties
128
. Thus, we characterized CRI in Ptx3
-/-
 mice. As shown in Fig. 24A, after 3 
weeks of DMBA/TPA treatments, PTX3-deficient skins were associated with increased 
neutrophil infiltration compared to PTX3-competent skins.  Accordingly, the MPO content (Fig. 
24B) was significantly higher in skin homogenates from Ptx3
-/-
 than Ptx3
+/+
 mice. In addition, 
Ptx3
+/
Ptx3
-/-
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CD31 immunostaining showed expanded angiogenesis in Ptx3
-/-
 compared to Ptx3
+/+
 skins (Fig. 
24C). 
 
Fig. 24. PTX3-deficiency is associated with increased CRI in early carcinogenesis.  
(A) Immunohistochemical analysis of neutrophil (Ly6G+) infiltration on PTX3-deficient and PTX3-competent 
skins. Mice are administered with DMBA/TPA for three weeks. Skin samples are collected 48 hours after the last 
TPA. Each dot represents the average of ten fields while the bar indicates the mean ± SEM. (B) MPO dosage by 
ELISA of skin homogenates from Ptx3
-/-
 and Ptx3
+/+
 mice (mean ± SEM). (C,D) Analysis of angiogenesis (CD31
+ 
immunoreactive area, IRA) in cutaneous early lesions by immunofluorescence. Each dot represents the average of 
ten fields while the bar indicates the mean ± SEM . *: p<0.05, **: p<0.01, unpaired Student's t test.  
 
Moreover, the concentration of pro-inflammatory cytokines IL-1α, IL-23 and the neutrophil 
attractant CXCL2 chemokine were significantly higher in Ptx3
-/- 
than in Ptx3
+/+ 
skin
 
homogenates (Fig. 25). Therefore, these data show that the lack of PTX3 is associated with 
increased neutrophil infiltration, MPO content as well as angiogenesis in early carcinogenesis. 
Moreover, PTX3-deficiency also correlates with higher levels of pro-inflammatory mediators. 
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Fig. 25. PTX3-deficiency is associated with increased pro-inflammatory cytokines and chemokines in early 
carcinogenesis.  
Analysis by ELISA of murine IL-1α, IL-23, TNF-α, IL-17, TGF-β and CXCL2 in skin homogenates from PTX3-
deficient and PTX3-competent mice. Dosage of CCL2, IL-6, IL-12 and IFN-γ displays undetectable levels (data not 
shown). Mice are treated with DMBA/TPA for three weeks. Skin samples are collected 48 hours after the last TPA. 
(mean ± SEM). *: p<0.05, unpaired Student's t test.  
 
4.4 PTX3-deficiency is associated with higher complement activation in the acute phase of 
carcinogenesis 
In addition to promoting complement activation during microbial infections, as described for A. 
fumigatus infection145, in sterile inflammation, including postischemic acute kidney injury156 or 
myocardial stroke
150
, PTX3 acts as a negative regulator of inflammation favoring FH activity. In 
3-MCA induced fibrosarcoma Ptx3
-/-
 lesions displayed higher C3 deposition than Ptx3
+/+
, likely 
through the missing interaction of PTX3 with FH. Thereby, we focused on complement 
activation in the murine model of DMBA/TPA-induced skin cancer. Since C3 represents the 
central element of the three complement pathways, we determined C3 deposition in both early 
and late carcinogenesis. Interestingly, as shown in Fig. 26A, PTX3-deficiency was associated 
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with increased cutaneous C3 levels after three weeks of DMBA/TPA treatments, compared to 
Ptx3
+/+
 treated-skins (p=0.04). In contrast, confocal analysis of C3 did not show significant 
differences between Ptx3
+/+
 and Ptx3
-/-
 papillomas in late carcinogenesis (Fig. 26B).  
 
 
 
Fig. 26. PTX3-deficiency is associated with higher complement activation in early carcinogenesis. (A) 
Confocal microscopy of C3 deposition on PTX3-deficient and PTX3-competent skins. Ptx3
-/-
 and Ptx3
+/+
 mice are 
administered with DMBA/TPA for three weeks. Skin samples are removed 48 hours after the last TPA. (B) 
Confocal microscopy of C3 deposition on PTX3-deficient and PTX3-competent papillomas removed after 22 weeks 
of DMBA/TPA. Each dot represents a single field (mean ± SEM). *: p<0.05, unpaired Student's t test. (C, D) 
Incidence and mean number of papillomas, respectively, in C3 deficient and PTX3/C3-deficient mice. One 
experiment with 16 C3
+/+
/PTX3
+/+
, 11 Ptx3
-/-
, 18 C3
-/-
/PTX3
-/-
 and 6 C3
-/-
 mice of 6-10 wks. *: p<0.05, **: p<0.01, 
paired Student’s test. 
 
 
To assess the role of complement in the phenotype of PTX3-deficient mice, we evaluated the 
tumor susceptibility of C3 deficient and PTX3/C3- double deficient mice in DMBA/TPA-
induced skin cancer.  
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As shown in Fig. 26C and D, C3-deficiency conferred protection in terms of both papilloma 
number and papilloma incidence compared to Ptx3
+/+
 mice (p=0.0038; p=0.03). These data 
indicate the role of complement in tumor-promoting inflammation in both mesenchymal and 
epithelial tumor models. However, in this preliminary experiment, C3-deficiency did not reduce 
the tumor susceptibility of Ptx3
-/-
 mice at the end of carcinogenesis (22 weeks). Then, these 
results suggest that the exacerbated inflammation of Ptx3
-/- 
papillomas is partially dependent on 
the effect of complement. 
 
4.5 PTX3-deficiency is associated with increased IgG1 levels in both early and late 
carcinogenesis 
In a genetic model of murine squamous carcinogenesis in which the early region genes of human 
papillomavirus type 16 (HPV16) are under control of skin keratin 14, Coussens et al. have 
demonstrated the protumorigenic role of immunoglobulins (Igs) in CRI through FcγR-dependent 
mast cell and neutrophil recruitment
112
. PTX3 acts as a functional ancestor of antibodies and 
plays opsonic activity via FcγR, possibly competing with Igs133.  
Thereby, we investigated IgG deposition during DMBA/TPA-induced carcinogenesis. 
Interestingly, confocal microscopy showed higher IgG1 levels in PTX3-deficient skins obtained 
after three weeks of DMBA/TPA treatments, compared to PTX3-competent skins (Fig. 27A). 
Increased IgG1 deposition was also observed in Ptx3
-/-
 papillomas taken during late 
carcinogenesis (30 weeks of DMBA/TPA treatments) compared Ptx3
+/+ 
papillomas (Fig. 27B). 
Further studies are needed to understand whether the increase of antibodies is responsible for 
higher inflammation of Ptx3
-/- 
mice in skin carcinogenesis and whether Fc Rs are involved in 
increased inflammation associated with carcinogenesis in PTX3-deficient mice. 
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Fig. 27. PTX3-deficiency is associated with increased IgG1 levels in both early and late carcinogenesis. 
Analysis by confocal microscopy of IgG1 levels in both short-term treated skins and papillomas, respectively, from 
PTX3-deficient and competent mice (each dot represents the average of ten fields and the bar indicates the mean ± 
SEM) *: p<0.05, unpaired Student's t test.  
 
4.6 PTX3-deficiency contributes to increased neutrophil infiltration in late carcinogenesis 
Several data from the literature indicate the protumorigenic role of neutrophils in DMBA/TPA-
induced skin cancer
56
. Immunohistochemical analysis displayed increased neutrophil infiltration 
(Ly6G
+
 cells) of Ptx3
-/-
 papillomas, collected 48 hours after 16 weeks of DMBA/TPA, compared 
to Ptx3
+/+ 
papillomas (Fig. 28A), similarly to what observed after short-term TPA treatments. 
As shown in Fig. 28B and C, macrophage (F4/80
+
) and T-lymphocyte (CD3
+
) infiltration did not 
significantly differ between Ptx3
-/-
 and Ptx3
+/+
 papillomas, although the number of samples 
should be increased.  
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Fig. 28. PTX3-deficiency is associated with higher CRI in late carcinogenesis. (A-B) Immunohistochemical 
analysis of neutrophil (Ly6G) in PTX3-deficient and PTX3-competent papillomas. (C-D) Immunohistochemical 
analysis of macrophage (F4/80) and T-cell (CD3) infiltration. Ptx3-deficient and Ptx3-competent mice are 
administered with DMBA/TPA for 16 weeks. Skin samples are collected 48 hours after the last TPA (each dot 
represents the average of ten fields, while the bar shows mean ± SEM). *: p<0.05, unpaired Student's t test.  
 
Furthermore, FACS analysis of circulating leukocytes from PTX3-deficient and competent mice 
treated with DMBA/TPA for 22 weeks displayed high level of neutrophils associated with 
PTX3-deficiency (Fig. 29). In addition, Ptx3
-/-
 mice exhibited increased circulating levels of 
CD4
+
 T cell compared to Ptx3
+/+
 mice. The capacity of CD4
+
 T-cells to favor the development of 
tumors is not without precedent. Yusuf et al. have demonstrated that CD4
−/− 
mice developed less 
papillomas than immunocompetent mice in DMBA cutaneous carcinogenesis
26
. However, the 
higher number of circulating CD4
+
 T cells associated with PTX3-deficiency is unexpected and 
not explained by knowledge of PTX3 function. The percentage of monocytes (CD11b
+
CD115
+
 
cells), DCs (CD11c
+
cells), NK cells (NK1.1
+
 cells), CTL (CD8
+
 cells) and B-cells (CD19
+
 cells) 
was comparable in the two groups (Fig. 29).  
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Fig. 29. FACS analysis of circulating leukocytes from PTX3-deficient and competent mice in late 
carcinogenesis. FACS analysis of circulating leukocytes from PTX3-deficient and competent mice treated with 
DMBA/TPA for 22 weeks. Blood samples are collected 48 hours after the last TPA (mean ± SEM). *: p<0.05, 
unpaired Student's t test. 
 
 
4.7 The protective role of PTX3 through the modulation of P-selectin-dependent neutrophil 
recruitment  
Since in DMBA/TPA chemically induced cancer the higher complement activation associated 
with PTX3-deficiency is not totally responsible for increased susceptibility to SCC, we have 
investigated a further mechanism used by PTX3 to modulate inflammation. PTX3 has been 
shown to regulate P-selectin-dependent neutrophil recruitment
151
. We thus investigated the tumor 
susceptibility of P-selectin
-/-
 and PTX3/P-selectin double deficient mice in DMBA/TPA-induced 
skin carcinogenesis. As shown in Fig. 30 A-B, P-selectin
-/-
 mice were strongly protected in terms 
of number and incidence of papillomas compared to immunocompetent mice after 22 weeks of 
DMBA/TPA treatments (p<0.0001; p<0.0011 respectively). Interestingly, P-selectin-deficiency 
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reverted the phenotype of Ptx3
-/-
 mice to the level of P-selectin
-/- 
mice in terms of both number 
and incidence of papillomas.  
 
Fig. 30. P-selectin-deficiency reverts the tumor susceptibility of Ptx3
-/- 
mice. Results are shown as (A) number of 
papillomas per mouse and (B) percentage of papilloma incidence in each group (mean ± SEM). Groups of female 
Ptx3
+/+
/Pselectin
+/+
, Ptx3
-/-
, P-selectin
-/- 
and Ptx3
-/-
P-selectin
-/-
 mice are treated with 25 μg DMBA, and 1 week later, 
thrice weekly with 4 μg TPA for 22 weeks. One experiment with 6 mice/group is shown. **: p<0.01, ***: p<0.001, 
paired Student's t test. (C) Immunohistochemical analysis of neutrophil (Ly6G+) infiltration in the skin. Groups of 
female Ptx3
+/+
/Pselectin
+/+
, Ptx3
-/-
, P-selectin
-/- 
and PTX3/P-selectin-double deficient
 
mice are administered with 
DMBA/TPA for three weeks. Skin samples are collected 48 hours after the last TPA. (D) Immunohistochemical 
analysis of neutrophil (Ly6G+) infiltration in papilloma recovered after 22 weeks of DMBA/TPA. Each dot 
represents the average of ten fields. *: p<0.05, **: p<0.01, unpaired Student's t test. 
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Moreover, immunohistochemical analysis of both short-term DMBA/TPA treated skins and 
papilloma, respectively, demonstrated a marked reduction of neutrophils (Ly6G+) associated to 
P-selectin
-/-
 and Ptx3
-/-
/P-selectin
-/-
 compared to Ptx3
-/-
 treated-skins (Fig. 30C-D). As shown in 
Fig. 31, FACS analysis of blood cells after 22 weeks of DMBA/TPA indicated comparable 
percentage of leukocytes between P-selectin-deficient and Ptx3/P-selectin double deficient mice. 
P-selectin-deficiency was associated with a circulating neutrophil accumulation possibly related 
to the inability of these cells to reach the tissues. In addition, low levels of circulating CD4
+
 T 
cells and CD19
+
 B cells were observed in P-selectin
-/-
 mice.  
 
Fig. 31. FACS analysis of circulating leukocytes from P-selectin deficient and PTX3/P-selectin double 
deficient mice in late carcinogenesis. FACS analysis of total leukocytes. Ptx3-, P-selectin- and PTX3/P-selectin- 
deficient and immunocompetent mice are treated with DMBA/TPA for 22 weeks. Blood samples are collected 48 
hours after the last TPA (mean ± SEM). *: p<0.05, unpaired Student's t test. 
 68 
Although P-selectin-deficiency did not affect the tumor susceptibility of Ptx3
-/-
 mice in 3-MCA-
carcinogenesis, our results suggest the tumor-promoting role of P-selectin in DMBA/TPA-
induced skin carcinogenesis possibly favoring an exacerbated neutrophil recruitment. Then, 
PTX3 plays a protective role in skin carcinogenesis as results of modulation of P-selectin-
dependent neutrophil recruitment. 
 
4.8 The in vivo neutrophil depletion reverts the tumor susceptibility of PTX3-deficient mice 
To assess the role of neutrophils in increased carcinogenesis to DMBA/TPA-induced skin 
carcinogenesis exhibited by Ptx3
-/-
 mice, we treated both PTX3-competent and deficient mice 
with an anti-Ly6G antibody throughout the DMBA/TPA experiment.  
As shown in Fig. 32A, neutrophil depletion did not affect the papilloma multiplicity of 
immunocompetent mice, whereas it decreased the susceptibility of Ptx3
-/-
 mice, reverting the 
phenotype. FACS analysis of blood cells, performed at the end of carcinogenesis, confirmed 
neutrophil depletion and did not show differences of circulating monocytes among groups (Fig. 
32B-C). 
Data obtained by P-selectin-deficient mice and Ly6G depletion, both dampening neutrophil 
infiltration, suggest the relevance of these cells in the exacerbated inflammation shown in Ptx3
-/- 
papillomas. 
Finally, we also used a genetic approach to address the relevance of neutrophils in this model. 
We treated both GCSFR-competent and deficient mice with DMBA/TPA for 22 weeks. CSF3R 
is the transmembrane receptor, for colony stimulating factor 3 (G-CSF), a cytokine that controls 
the production, differentiation, and function of granulocytes
168
. As shown in Fig. 32D-E, Csfgr
-/- 
mice were protected in terms of both papilloma number and incidence (p<0.01; p<0.003, 
respectively).  
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Fig. 32. Role of neutrophils in skin carcinogenesis. (A) Number of DMBA/TPA-induced papillomas in Ptx3
-/- 
and 
Ptx3
+/+
 mice treated with anti-Ly6G, or isotype mAb, twice weekly for 22 weeks throughout the DMBA/TPA 
experiment (results shown as mean ± SEM). One experiment with 6 mice/group. **: p<0.01, ***: p<0.001, paired 
Student's t test. (B, C) FACS analysis of circulating neutrophils (Ly6G
+
) and monocytes (CD11b
+
CD115
+
) at 22 
weeks of DMBA/TPA (mean ± SEM). *: p<0.05,  ****: p<0.001, unpaired Student's t test. (D, E) Percentage of 
papilloma number and incidence in each group (mean ± SEM). Groups of 10 female Csfgr
-/- 
and Csfgr
+/+
 mice are 
treated with 25 μg DMBA, and 1 week later, three times weekly with 4 μg TPA for 22 weeks. **: p<0.01, *: p<0.05, 
paired Student's t test. 
 
 
 
FACS analysis of circulating leukocytes from CSFGR-deficient and competent mice treated with 
DMBA/TPA for 22 weeks displayed a severe neutropenia associated with CSFGR-deficiency 
(Fig. 33). In addition, Csfgr
-/-
 mice exhibited high circulating levels of CD8
+
 T cells, which were 
known to play a protective role in skin tumor development
26
.  
All together these approaches demonstrate the pro-tumorigenic role of neutrophils in chemically 
induced SCC. 
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Fig. 33. FACS analysis of circulating leukocytes from CSFGR deficient and competent mice in late 
carcinogenesis. FACS analysis of total leukocytes. CSFGR-deficient and immunocompetent mice are treated with 
DMBA/TPA for 22 weeks. Blood samples are collected 48 hours after the last TPA (mean ± SEM). *: p<0.05, 
****: p<0.001, unpaired Student's t test. 
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5 Materials and methods 
5.1 Animals. Wild-type C57BL/6J male mice were obtained from Charles River Laboratories, 
Calco, Italy. PTX3-deficient mice were generated by Garlanda et al.130. P-Selectin-/-, C3-/- and 
Gcsfr
-/-
 mice were purchased from The Jackson Labs, Bar Harbor ME, USA. PTX3/C3 and 
PTX3/P-selectin double deficient mice were generated by crossing PTX3- and C3- or P-selectin 
deficient mice. All mice were used on a C57BL/6J genetic background. Mice were housed in the 
SPF animal facility of Humanitas Clinical and Research Center in individually ventilated cages. 
Procedures involving animals handling and care were conformed to protocols approved by the 
Humanitas Clinical and Research Center (Rozzano, Milan, Italy) in compliance with national 
(4D.L. N.116, G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council 
Directive 2010/63/EU, OJ L 276/33, 22-09-2010; National Institutes of Health Guide for the 
Care and Use of Laboratory Animals, US National Research Council, 2011). The study was 
approved by Italian Ministry of Health (approval n. 71/2012-B, issued on the 09/03/2012). All 
efforts were made to minimize the number of animals used and their suffering.  
 
5.2 Carcinogenesis model. Skin carcinogenesis was performed as reported (Schioppa et al., 
2011) in a two-step DMBA/TPA model. Initiation was accomplished by pipetting 25μg of 
DMBA (Sigma-Aldrich) in acetone onto shaved back skin of 6-7-weeks old female mice. The 
target age for beginning DMBA/TPA skin carcinogenesis were 6-7 weeks of age because most 
of mice are in the resting phase of hair cycle. Promotion, begun 1 week after the initiation, was 
performed three times a week with 4μg of TPA (Sigma-Aldrich) from week 1 to week 30. 
During the experiment, mice were monitored weekly for papilloma/carcinoma development. 
Only palpable tumors larger than 1 mm or present for at least a week were counted. Papilloma 
started to develop from the eighth or ninth week. Papilloma converted to SCC after at least 20 
 72 
weeks of promotion
117
. Four experiments with 10 female Ptx3
-/- 
and Ptx3
+/+
 mice and one 
experiment with 6-18 female P-selectin
-/-
, C3
-/-
, Cfs3r
-/-
,
 
PTX3
-/-/C3-/- and Ptx3-/-/P-selectin-/- 
mice were performed. 
 
5.3 Blocking of Ly6G in vivo. 6 Ptx3
+/+
 and 6 Ptx3
-/- 
mice were treated one day before DMBA 
treatment with 200μg of specific Ab (control rat IgG2A, Clone 2A3; or rat anti-Ly6G, Clone 
1A8) and than every three days with 100μg for the entire duration of the experiment (22 weeks). 
To evaluate neutrophil/Ly6G+ cell depletion, 200μl blood was collected by retro-orbital sinus of 
anesthetized mice into EDTA-containing tubes at the second week and the end of DMBA/TPA 
treatment. Red blood cells were lysed in 0.8% NH4Cl, 0.1 mM EDTA for 20 minutes on ice. 
Then, lysed blood samples were washed twice in PBS
-/- 
1X and centrifuge at 2500 rpm for 20 
min at 4°C. Plasma was removed and the pellets were stained in the dark for 30 min at 4° C with 
fluorescent Ab against CD45 (CD45-BV605; clone 30-F11), CD11b (CD11b-BV421; clone M1-
70), Ly6G (Ly6G PE-CF-594, clone 1A8) and CD115 (CD115-APC, clone AFS98) from BD 
Bioscience, eBioscience or BioLegend in 50 l FACS buffer (2% FBS, 2mM EDTA, 0,05% 
NaN3 in PBS
-/-
 1X). Cells were washed in FACS buffer and fixed with 300 l formalin (2%) in 
PBS
-/-
 1X. Cells were analysed by cytometry on LSR Fortessa (BD Bioscience).  
 
5.4 ELISA. 5 untreated or vehicle (acetone) skins and cutaneous samples treated 1 or 5 times 
with DMBA/TPA, respectively, were recovered 12 hours after the last TPA from Ptx3
+/+ 
mice. 
Moreover, Ptx3
+/+
 papillomas were removed 24 hours after 16 weeks of DMBA/TPA. Skin 
samples or papillomas were homogenized in 1ml PBS with Ca
2+
/Mg
2+ 
(PBS
+/+
) containing 
protease inhibitors (Complete
®
-EDTA-free; Roche Diagnostics) and PMSF (1mM). Tissue 
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homogenates were centrifuged at 14000 rpm for 30 min at 4 °C. Then, supernatants were 
quantified by Coomassie plus protein assay reagent (Thermo Scientific) and stored at -20 °C for 
PTX3 analysis by ELISA (R&D DuoSet ELISA Development System) according to 
manufacturer’s instructions. Skin samples treated for 3 weeks with DMBA/TPA and recovered 
24 hours after the last TPA, from 7 Ptx3
+/+
 and 6 Ptx3
-/- 
mice, were homogenized, and quantified, 
as described above, for cytokine analysis. Murine IL-1α, IL-23, TNF-α, IL-17, TGF-β, CXCL2, 
CCL2, IL-6, IL-12, IFN-γ and MPO were measured in tissue homogenates by ELISA (R&D 
DuoSet ELISA Development System) according to manufacturer’s instructions.  
 
5.5 FACS analysis. Blood was collected by retro-orbital sinus of 6 anesthetized experimental 
groups (6 Ptx3
+/+
/P-selectin
+/+
, 9 Ptx3
-/-
, 6 P-selectin-/-, 6 Ptx3-/-/P-selectin-/- mice, 10 Gcsfr+/+ 
and 6 Gcsfr
-/-
), after 22 weeks of DMBA/TPA treatments, into EDTA-containing tubes. Red 
blood cells were lysed in 0.8% NH4Cl, 0.1 mM EDTA for 20 minutes on ice. Then, lysed blood 
samples were washed twice in PBS
-/- 
1X and centrifuge at 2500 rpm for 20 min at 4°C. Plasma 
was removed and the composition of leukocytes in the blood was determined by flow cytometry 
using the combination of following antibodies: CD45-BV605 (clone 30-F11); CD3e-FITC (clone 
145-2C11); CD8-PE (clone 53-6.7); CD4-Alexa700 (clone RM4-5); CD19-Pacific Blue (clone 
1D3); Ly6G PE-CF-594 (clone 1A8); CD11b-BV421 (clone M1-70); CD115-APC (clone 
AFS98); CD11c-Alexa700 (clone N418); T cells/Not CD4 Not CD8 NK1.1-APC (clone PK136) 
from BD Bioscience, eBioscience or BioLegend. NKT cells were characterized as CD3
+
CD4
-
CD8
-
 T cells. Cells were analysed on LSR Fortessa (BD Bioscience).  
 
5.6 Haematoxylin-Eosin (H&E) At least 10 samples from Ptx3
+/+
 and Ptx3
-/-
 OCT-embedded 
mouse papillomas recovered after 16 or 30 weeks of DMBA/TPA treatments were analysed. 
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Skin tissues were fixed in 4% PFA, washed twice in PBS, dehydrated in 20, 30 and 40% sucrose 
solutions gradient, mounted in OCT embedding compound and stored at -80°C. Eight-μm 
consecutive sections were cut from the middle of the tissue and used for histological examination 
in each mouse. Sections for histological analysis were fixed in 4% formalin and stained with 
haematoxylin (2-3 min) and eosin (10 dives). Then, sections were dehydrated in increasing 
concentrations of alcohols (70%-90%-100%-100%), clarified in xylene and analysed by a 
pathologist.  
 
5.7 Immunohistochemistry. Skin samples treated one time with DMBA/TPA were recovered 
12 hours after the last TPA from Ptx3
+/+
 mice. Ptx3
+/+
 papillomas were removed 24 hours after 
16 weeks of DMBA/TPA. Ptx3
-/-
 tissues were used as negative control. Then, treated-skins or 
papillomas were fixed in 4% PFA, washed twice in PBS, dehydrated in 20, 30 and 40% sucrose 
solutions gradient, mounted in OCT embedding compound and stored at -80°C. Eight-μm 
consecutive sections were cut from the middle of the tissue and used for PTX3 
immunohistochemistry. Endogenous peroxidase was blocked for 5 min with a Peroxidized 1 
(Biocare Medical) ready to use. Unspecific sites were blocked with Rodent Block M (Biocare 
Medical) 30 min and tissues were incubated for two hours with affinity-purified Ig against PTX3 
(rabbit polyclonal IgG) in PBS supplemented with BSA (2%) and NP40 (0.02%). Envision
+ 
System HRP Labelled Polymer anti Rabbit (Dako) was used as secondary antibody for 30 
minutes. After washing, slides were developed with DAB (3,3’-diaminobenzidine) (Biocare 
Medical) and counterstained with Hematoxilyn. Tissues were dehydrated with ethanol, mounted 
with Eukitt and analysed with an Olympus BX61 virtual slide scanning system.  
Skin samples collected 24 hours after 3 weeks of DMBA/TPA and papillomas obtained 24 hours 
after 16 weeks of DMBA/TPA, from Ptx3
+/+
 and Ptx3
-/- 
mice, were processed, as described 
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above, and stained for one hour with high affinity-purified Ig against F4/80 (rat-anti mouse; 
clone FA-11; Hycult® Biotech), Ly6G (rat-anti mouse; clone 1A8; BD Bioscience), CD3 (rat-
anti human/mouse; clone CD3-12; AbD Serotec). Rat on Mouse HRP-Polymer kit (Biocare 
Medical) was used as secondary antibody in PBS supplemented with BSA (2%) and NP40 
(0.02%). After washing, slides were developed with DAB (3,3’-diaminobenzidine) (Biocare 
Medical) and counterstained with Hematoxilyn. Tissues were dehydrated with ethanol, mounted 
with Eukitt and analysed with an Olympus BX61 virtual slide scanning system. 
Skin samples collected 48 hours after 3 weeks of DMBA/TPA and papillomas obtained 24 hours 
after 22 weeks of DMBA/TPA, from Ptx3
+/+
P-selectin
+/+
, P-selectin
-/-
, Ptx3
-/-
, Ptx3
-/-
P-selectin
-/- 
mice, were processed, as described above, and stained for one hour with high affinity-purified Ig 
against Ly6G (rat-anti mouse; clone 1A8; BD Bioscience). Rat on Mouse HRP-Polymer kit 
(Biocare Medical) was used as secondary antibody in PBS supplemented with BSA (2%) and 
NP40 (0.02%). After washing, slides were developed with DAB (3,3’-diaminobenzidine) 
(Biocare Medical) and counterstained with Hematoxilyn. Tissues were dehydrated with ethanol, 
mounted with Eukitt and analysed with an Olympus BX61 virtual slide scanning system. 
 
5.8 Immunofluorescence. Skin tissues treated with a single application of DMBA/TPA and 
recovered after eight hours from Ptx3
+/+ 
mice were fixed in PFA (4%), washed twice in PBS, 
dehydrated in 20, 30 and 40% sucrose solution gradient, mounted in OCT embedding compound 
and stored at -80°C. Eight-μm consecutive sections were cut, mounted on Superfrost slides and 
fixed in 4% PFA for 15 min, rehydrated in PBS and blocked in 5% normal goat (Dako, 
Denmark) or donkey (Sigma- Aldrich) serum, 2% BSA, 0.1% Triton® X-100 (Sigma-Aldrich) in 
PBS
+/+ 
pH 7.4 for 1h at room temperature. Sections were incubated with the following primary 
antibodies for 2h at room temperature: affinity purified rabbit polyclonal IgG anti-PTX3 or goat 
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IgG anti-mouse PTX3 (R&D Systems); rat anti-mouse F4/80 (Clone FA-11; Hycult® Biotech) 
or rat anti-mouse Ly6G (Clone 1A8; BD Bioscience). Ptx3
+/+
 and Ptx3
-/-
 papillomas obtained 
after 16 and 30 weeks of DMBA/TPA administration were processed, as described above, and 
stained with the following primary antibodies for 2h at room temperature: affinity purified goat 
polyclonal IgG anti-mouse PTX3 (R&D Systems) and rabbit polyclonal anti-mouse LYVE-1 
(Abcam); FITC-conjugated goat F(AB’)2 fragment to mouse Complement C3 (Cappel, MP 
biomedical); goat polyclonal anti-mouse IgG1 (Southern Biotech);  rabbit anti-mouse Keratin 1 
(AF109; Covance) and rabbit anti-mouse Keratin 14 (AF64; Covance), respectively. Skin 
samples taken after three weeks of treatments, were processed, as discussed, and stained with 
goat polyclonal anti-mouse IgG1 (Southern Biotech) or FITC-conjugated goat F(AB’)2 fragment 
to mouse Complement C3 (Cappel, MP biomedical). After washing, sections were incubated for 
1h with the following species-specific cross-adsorbed detection antibodies: Alexa® Fluor 488-
conjugated donkey or goat anti-rabbit; Alexa® Fluor 647- conjugated donkey anti-goat by 
Invitrogen- Molecular Probes and Alexa  Fluor 594-conjugated donkey or goat anti-rat by 
Invitrogen-Molecular Probes. For DNA detection, DAPI (300nM; Invitrogen-Molecular Probes) 
was used. After each step, sections were washed with PBS
+/+ 
pH 7.4 containing 0.01% (v/v) 
Tween® 20. Sections were mounted with the antifade medium FluorPreserve Reagent 
(Calbiochem) and analysed with an Olympus Fluoview FV1000 laser scanning confocal 
microscope with 10X (N. A. 0.4). Negative controls were obtained by omission of the primary 
antibody or using Ptx3
-/-
, C3
-/- 
tissues. 
 
5.9 Statistical analysis. All values were expressed as mean ± SEM. Unpaired Student’s t test, 
paired Student’s t test, chi-square test were used as specified. p ≤ 0.05 was considered 
significant. Statistics were calculated with GraphPad Prism version 5, GraphPad Software.  
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Discussion 
The general aim of this research was to question the role of the humoral arm of innate immunity 
in tumor-promoting inflammation using the long pentraxin PTX3 as a paradigm
128
. Previous 
observations by our group demonstrated increased susceptibility to 3-MCA-induced 
mesenchymal cancer in PTX3-deficient mice. This phenotype was associated with increased 
macrophage infiltration, cytokine production, angiogenesis, and genetic instability as revealed by 
an increased frequency of Trp53 mutations, oxidative DNA damage and expression of DDR 
markers in Ptx3
-/- mice. Several lines of evidence indicate that PTX3-deficiency triggers an 
exacerbated Complement activation, because of defective recruitment of the negative regulator 
Factor H, with higher production of C5a, CCL2 and increased number of tumor-promoting 
macrophages with an M2-like phenotype in 3-MCA-induced fibrosarcoma.  
In selected human tumors (e.g. leiomyosarcomas, CRC, SCC) PTX3 expression was 
regulated epigenetically by methylation of the promoter region and of a putative enhancer. Thus, 
a crucial component of the humoral arm of innate immunity and regulator of Complement 
activation acts as an extrinsic oncosuppressor by dampening Complement-mediated, 
macrophage-sustained, tumor promoting inflammation.  
Since previous studies demonstrated the protective role of PTX3 in cancer-related 
inflammation (CRI), in a murine model of mesenchymal cancer, we also addressed the role of 
PTX3 in murine model of epithelial origin, DMBA/TPA chemically induced skin cancer, 
focusing on other potential mechanisms causing CRI, in addition to the effect of macrophages 
and Complement. 
The primary first experiments investigated PTX3 production throughout DMBA/TPA-induced 
skin carcinogenesis. During early carcinogenesis PTX3 was abundantly produced in the skin by 
infiltrating leukocytes, vessels and interstitial stroma. In late carcinogenesis, throughout chronic 
treatments with TPA, PTX3 was low and expressed mainly by the extracellular matrix.  
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PTX3-deficiency was associated with increased susceptibility to DMBA/TPA-induced 
skin cancer in terms of both papilloma number and incidence. Moreover, histological analysis 
and the expression profile of specific keratin proteins demonstrated a more aggressive behaviour 
of PTX3-deficient lesions, suggesting the protective role of PTX3 in both mesenchymal and 
epithelial murine models of cancer.  
Further experiments were needed to characterize the molecular mechanisms, which 
explained the protective role of PTX3 in mouse skin carcinogenesis. PTX3 is a humoral pattern 
recognition molecule essential for resistance against selected pathogens including A. 
fumigatus130, P. aeruginosa135, uropathogenic E. coli127. PTX3 has antibody-like properties, such 
as recognition of microbial moieties
160
, opsonization via Fcγ receptors133, Complement 
activation and regulation of inflammation
148,161
. Indeed, it has long been known that Ptx3
-/-
 mice 
display an exacerbated inflammation in diverse experimental models
155,156,157
. The enhanced 
inflammatory reactions observed in PTX3-deficient mice have been attributed to the regulation 
of Complement activation
150
 or to the interaction with P-selectin mediated by PTX3
151
. 
Considering that tumor promoting inflammation is now recognized as an essential component of 
the tumor microenvironment
2,5
, the increased susceptibility of PTX3-deficient mice to 
carcinogenesis is a reflection of its regulatory function on inflammation.  
The biochemical and histological analysis of DMBA/TPA-treated skins showed the 
association between PTX3-deficiency and higher neutrophil infiltration and myeloperoxidase 
content in both early and late carcinogenesis. In addition, PTX3-deficiency was associated with 
higher level of the neutrophil-attractant CXCL-2 as well as pro-inflammatory mediators 
including IL-1 , IL-23. Both molecules are potent tumor-promoting cytokines
30,120
. 
Interestingly, Ptx3
-/-
 skins showed high level of angiogenesis, consistent with a pro-angiogenic 
function of tumor-associated neutrophils
68
.  
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It was therefore important to explain the relevance of neutrophils in the enhanced 
carcinogenesis of Ptx3
-/-
 mice. The tumor-promoting functions of neutrophils are not without 
precedent and consist of reactive oxygen species-dependent and independent mechanisms
51,64
. 
The expression of the neutrophil chemokine receptor CXCR2 has been correlated to tumor 
progression. Short-term depletion of Ly6G
+
 cells in established papillomas reduced their number 
and size
56
. Then, we used three different approaches, including P-selectin-deficient mice, a 
blocking antibody against Ly6G, and a genetic model of neutropenia, to address the role of 
neutrophils in skin carcinogenesis. 
PTX3 has been shown to regulate P-selectin-dependent neutrophil recruitment in selected 
experimental models
151,157
. Accordingly, we interrogated the tumor susceptibility of P-selectin- 
and PTX3/P-selectin- double deficient mice in DMBA/TPA-induced skin carcinogenesis. P-
selectin
-/-
 mice were strongly protected. Interestingly, P-selectin deficiency reverted the 
phenotype of Ptx3
-/-
 mice to the level of P-selectin
-/- 
mice and reduced the neutrophil infiltration 
in both early and late carcinogenesis. Thus, these results suggest a mechanism of PTX3-mediated 
protection as a result of modulation of P-selectin-dependent neutrophil recruitment. However, 
the P-selectin pathway, as well as neutrophils, was not involved in the enhanced susceptibility to 
3-MCA-carcinogenesis of Ptx3-deficient mice. These different results could be a consequence of 
the diversity of CRI in different organs or tumors
162
. 
The treatments with an antibodies direct against Ly6G throughout skin carcinogenesis 
reverted the phenotype of PTX3-deficient mice in terms of increased papilloma number. Thus, 
neutrophils represent the main actors for exacerbated inflammation in Ptx3
-/- 
papilloma.  
Finally, the use of Csf3r
-/-
 mice, a genetic model of neutropenia, confirmed the relevance 
of neutrophil in CRI throughout mouse skin carcinogenesis.   
PTX3 dampens inflammation favoring FH activity
148
. In 3-MCA induced fibrosarcoma 
Ptx3
-/-
 lesions displayed higher C3 deposition than Ptx3
+/+
, likely through the missing interaction 
of PTX3 with FH. Thereby, we focused on complement activation in the murine model of 
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DMBA/TPA-induced skin cancer. PTX3-deficiency was associated with increased cutaneous C3 
levels in early carcinogenesis. To assess the role of complement in the phenotype of PTX3-
deficient mice, we evaluated the tumor susceptibility of C3- deficient and PTX3/C3- double 
deficient mice in DMBA/TPA-induced skin cancer. Similarly to what observed in 3-MCA-
carcinogenesis, C3-deficient mice are strongly protected against DMBA/TPA carcinogenesis. 
The results obtained here suggest that Complement is a key component of tumor-promoting 
cancer-related inflammation in both mesenchymal and epithelial cancers. In contrast to that 
observed in 3-MCA-carcinogenesis, in this preliminary experiment, C3-deficiency did not 
completely rescue the tumor susceptibility of Ptx3
-/-
 mice in DMBA/TPA-induced late 
carcinogenesis suggesting that the exacerbated inflammation of Ptx3
-/-
 papillomas is only 
partially dependent from the effect of Complement.  
 Antibodies have been shown to orchestrate CRI in a genetic model of epithelial 
carcinogenesis through FcγR-dependent mast cell and neutrophil recruitment112. PTX3 acts as a 
functional ancestor of antibodies and plays opsonic activity via FcγR, possibly competing to 
immunoglobulins
133
. PTX3-deficiency was associated with higher IgG1 deposition in both early 
and late carcinogenesis but currently we do not know whether this increase is responsible of 
higher inflammation observed in PTX3-deficient mice in chemically induced SCC. 
Therefore, data derived by the investigation of three mechanisms, including the P-
selectin-pathway, as well as the pharmacological and genetic approach to dampen neutrophil 
component, demonstrate the relevance of neutrophils for exacerbated inflammation of PTX3-
deficient mice and their protumoral activity in chemically induced SCC. 
The results obtained by our group, including my thesis work, suggest that a regulatory 
component of the humoral arm of innate immunity, PTX3, acts as an extrinsic oncosuppressor 
gene in mouse and human.  Although the link between inflammation and cancer has long been 
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recognized
2,5
, the role of humoral innate immunity and, in particular, the complement had never 
been investigated before. 
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